Addressing a Public Health Crisis: Opioid Dependence

MARCH 28–APRIL 1, 2015

Hyatt Regency Atlanta

www.aatod.org
CONFERENCE OBJECTIVES

- To present the latest evidence relevant to the field and critically evaluate the implications for patients, clinicians, administrators, and policy makers
- To disseminate evaluation and treatment techniques to better serve patients and providers, improve program development and administration, and enhance patient outcomes
- To improve the collaboration between Opioid Treatment Programs and community partners in response to the heightened risks associated with the use of opioids
- To develop strategies to assist healthcare partnerships and collaborations by advancing their understanding of medication assisted treatment as a crucial element to community wellness in an era of healthcare reform
- To formulate methods to promote, support, facilitate, and integrate medication assisted treatment into the judicial and penal systems, government, and social service organizations
- To discuss the magnitude and impact of prescription opioids on the healthcare system and Opioid Treatment Programs

CONFERENCE PLANNING COMMITTEE

Jonathan P. Connell, MA  
*Conference Chair*
Opioid Treatment Providers of Georgia  
Private Clinics and TLC Clinic  

Mark W. Parrino, MPA  
*President*
American Association for the Treatment of Opioid Dependence, Inc.  

Carleen Maxwell-Taylor, MPH  
*Project Director*
American Association for the Treatment of Opioid Dependence, Inc.  

Angelina Budija  
*Administrative Coordinator*
American Association for the Treatment of Opioid Dependence, Inc.  

Alexandra Springer, CMP  
*Meetings and Exhibits Manager*
Talley Management Group, Inc.  

BOARD OF DIRECTORS

Mark W. Parrino, MPA  
*President*
NY  

Janice F. Kauffman, RN  
*First Vice President*
MA  

George E. Stavros, MD  
*Second Vice President*
AZ  

Michael Rizzi  
*Treasurer*
RI  

Tina Beckley, MA  
*Secretary*
CO

BOARD MEMBERS

Tim Bohman  
IN  

Roye T. Brown, MS  
LA  

Susan Case, MS  
AL  

W. Jonas Coatsworth, MA  
SC  

Debbie Crowley  
TN  

Brian Crissman, BA  
DC  

Emilia Figueroa Guillen, MD  
Mexico  

Richard Froncillo, LCDS  
PA  

Cheryl L. Gardine, LCSW  
MO  

Gloria Hanania, LMHC  
FL  

Edward J. Higgins, MA  
NJ  

Keith Hochadel, MEd  
OH  

Kenny House, LCAS  
NC  

Ron Jackson, LICSW  
WA  

Ann Jamieson, MS  
OK  

Jason Kletter, PhD  
CA  

Shirley Linzy, RNMS  
NV  

Kate Mahoney, LCSW  
IL  

Brian McCarron, DO  
MI  

Paul McLaughlin, MA  
CT  

Joel Millard, DSW  
UT  

Jennifer Minthorn, MA  
ME  

Edward V. Ohlinger  
VA  

Stacey Pearce  
GA  

Allegra Schorr  
NY  

Kenneth Stoller, MD  
MD

Member-At-Large

Richard Bilangi, MS

2015 CONFERENCE COMMITTEES

**Accreditation Committee**
Brian Crissman, BA  
*Committee Chair*

Carleen Maxwell–Taylor, MPH  
Alexandra Springer, CMP  
Susan Storti, PhD

**Awards Committee**
Ann Jamieson, MS  
*Committee Chair*

Susan Case, MS  
Jonas Coatsworth, MA  
Gloria Hanania, LMHC  
Michael Rizzi

**Hospitality Committee**
Brook Etherington, MA  
*Committee Chair*
Dear Colleagues, Patients, Advocates, Stakeholders, and Friends:

The Opioid Treatment Providers of Georgia (OTPG) and Georgia’s Department of Behavioral Health and Developmental Disabilities (DBHDD) welcome you to the 2015 American Association for the Treatment of Opioid Dependence, Inc. (AATOD) Conference! This year’s conference theme of “Addressing a Public Health Crisis: Opioid Dependence” comes at a unique time in the history of our nation and Medication Assisted Treatment. The focus on prescription opioid and heroin overdoses has brought forth several people at the state and federal levels who are providing leadership on how Medication Assisted Treatment is an integral part of addressing this public health crisis. As you know, there is a lot of work left to do at the local level to confront this growing health crisis and to educate others about Medication Assisted Treatment.

All planning committees have worked diligently to make this conference a truly exceptional event. As you review the topics for the Pre-Conference training opportunities, Plenary Sessions, Workshop Sessions, Poster Sessions, and Hot Topic Roundtables, you will clearly note their efforts to provide you with an outstanding training and policy event centered on Medication Assisted Treatment. I encourage you to take part in all of our sessions, spend time in our exhibition hall, and network with your colleagues. Make time to view the research posters and attend the Poster Author Session that will be held in the Grand Hall. Also take advantage of the opportunity to contribute and be heard at one of the Hot Topic Roundtables. Each element of the conference is filled with information and ideas to improve our programs and the treatment field as a whole. The clinic tours on Wednesday are a rare chance to see into the world of other facilities.

The Awards Banquet on Tuesday evening will be an elegant celebration to honor those who have made significant contributions to our field. We hope you will join us in acknowledging these individuals by attending this exciting event.

Finally, I ask that you help with the planning of our next conference by completing the evaluations at the end of each session, as well as at the conclusion of the conference. Your comments and suggestions will be carefully reviewed and will greatly assist in the development of the 2016 Conference in Baltimore, Maryland.

I hope you enjoy the conference in the beautiful city of Atlanta. I look forward to meeting each of you. Please take the time to enjoy Atlanta, renowned for its natural beauty, award winning restaurants, and thrilling entertainment; you don’t want to miss out on this stunning city. Our volunteers are available to offer suggestions and assist you with arrangements. Enjoy the conference.

Jonathan P. Connell, MA
2015 Conference Chair
<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, March 28</td>
<td>7:30 a.m.–5:00 p.m.</td>
<td>Registration Open</td>
</tr>
<tr>
<td>Saturday</td>
<td>8:00 a.m.–5:00 p.m.</td>
<td>The Certified Medication Assisted Treatment Advocate (CMA) Training Course</td>
</tr>
<tr>
<td>Saturday</td>
<td>8:00 a.m.–5:00 p.m.</td>
<td>State Opioid Treatment Authorities Training (Invitation Only)</td>
</tr>
<tr>
<td>Saturday</td>
<td>8:00 a.m.–5:30 p.m.</td>
<td>Buprenorphine for the Treatment of Opioid Dependence in Office-Based Treatment and OTPs</td>
</tr>
<tr>
<td>Saturday</td>
<td>9:00 a.m.–12:00 p.m.</td>
<td>Opioid Dependence in Peri-Partum Women: Policy, Collaboration, and Strategy</td>
</tr>
<tr>
<td>Saturday</td>
<td>9:00 a.m.–5:00 p.m.</td>
<td>Opioid Treatment Program Clinical Staff Education: The Use of Approved Medications in MAT</td>
</tr>
<tr>
<td>Saturday</td>
<td>1:00 p.m.–4:00 p.m.</td>
<td>Nurses and Opioid Treatment Programs</td>
</tr>
<tr>
<td>Saturday</td>
<td>1:00 p.m.–5:00 p.m.</td>
<td>Countering Opioid Stigma: Communicating Messages to Influence Public Perception</td>
</tr>
<tr>
<td>Saturday</td>
<td>1:00 p.m.–5:00 p.m.</td>
<td>New &amp; Emerging Medications for Treating Opioid Use Disorder</td>
</tr>
<tr>
<td>Saturday</td>
<td>5:00 p.m.–8:30 p.m.</td>
<td>AATOD Open Board Meeting</td>
</tr>
<tr>
<td>Sunday, March 29</td>
<td>7:30 a.m.–7:30 p.m.</td>
<td>Registration Open</td>
</tr>
<tr>
<td>Sunday</td>
<td>8:00 a.m.–5:30 p.m.</td>
<td>Opioid Maintenance Pharmacotherapy: A Course for Clinicians</td>
</tr>
<tr>
<td>Sunday</td>
<td>8:30 a.m.–12:30 p.m.</td>
<td>Countering Opioid Stigma: Communicating Messages to Influence Public Perception</td>
</tr>
<tr>
<td>Sunday</td>
<td>8:30 a.m.–12:30 p.m.</td>
<td>Intersection of Pain and Opioid Addiction: Research and Clinical Practice</td>
</tr>
<tr>
<td>Sunday</td>
<td>8:30 a.m.–5:30 p.m.</td>
<td>State Opioid Treatment Authorities’ Meeting (Closed Session for State and Federal Officials)</td>
</tr>
<tr>
<td>Sunday</td>
<td>9:00 a.m.–12:00 p.m.</td>
<td>Opioid Treatment Program Accreditation Town Hall Meeting</td>
</tr>
<tr>
<td>Sunday</td>
<td>9:00 a.m.–12:00 p.m.</td>
<td>Recovery and Medication Assisted Treatment</td>
</tr>
<tr>
<td>Sunday</td>
<td>1:00 p.m.–4:00 p.m.</td>
<td>Managing Workplace Risks: 10 Things Employers Need to Know</td>
</tr>
<tr>
<td>Sunday</td>
<td>1:00 p.m.–4:00 p.m.</td>
<td>OTP Liability for Patient-Related Motor Vehicle Accidents: A Mock Trial and Focus Group Presentation</td>
</tr>
<tr>
<td>Sunday</td>
<td>1:00 p.m.–5:00 p.m.</td>
<td>Presentations by the World Federation for the Treatment of Opioid Dependence (WFTOD)</td>
</tr>
<tr>
<td>Sunday</td>
<td>1:00 p.m.–5:00 p.m.</td>
<td>Overdose Prevention Implementation Strategies</td>
</tr>
<tr>
<td>Sunday</td>
<td>4:00 p.m.–7:30 p.m.</td>
<td>Posters in Grand Hall</td>
</tr>
<tr>
<td>Sunday</td>
<td>4:00 p.m.–7:30 p.m.</td>
<td>Exhibits</td>
</tr>
<tr>
<td>Sunday</td>
<td>5:30 p.m.–7:30 p.m.</td>
<td>Welcome Reception in Exhibit Hall</td>
</tr>
<tr>
<td>Sunday</td>
<td>7:30 p.m.–8:30 p.m.</td>
<td>Methadone Anonymous Meeting (Open)</td>
</tr>
<tr>
<td>Monday, March 30</td>
<td>7:30 a.m.–5:30 p.m.</td>
<td>Registration Open</td>
</tr>
<tr>
<td>Monday</td>
<td>7:30 a.m.–8:30 a.m.</td>
<td>Continental Breakfast in Exhibit Hall</td>
</tr>
<tr>
<td>Monday</td>
<td>7:30 a.m.–8:45 a.m.</td>
<td>Poster Author Session—Author(s) presentation including Q&amp;A</td>
</tr>
<tr>
<td>Monday</td>
<td>7:30 a.m.–4:30 p.m.</td>
<td>Exhibits (Exhibit Hall closed 9:30 a.m.–11:30 a.m.)</td>
</tr>
<tr>
<td>Monday</td>
<td>7:30 a.m.–4:30 p.m.</td>
<td>Posters in Grand Hall</td>
</tr>
<tr>
<td>Monday</td>
<td>8:45 a.m.–10:15 a.m.</td>
<td>Opening Plenary Session—Challenges and Opportunities to Impact the Opioid Dependence Crisis</td>
</tr>
<tr>
<td>Monday</td>
<td>10:30 a.m.–12:00 p.m.</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td>Monday</td>
<td>11:30 a.m.–4:30 p.m.</td>
<td>Exhibits</td>
</tr>
<tr>
<td>Monday</td>
<td>12:00 p.m.–1:30 p.m.</td>
<td>Lunch (on your own)</td>
</tr>
<tr>
<td>Monday</td>
<td>1:30 p.m.–3:00 p.m.</td>
<td>Workshop Sessions / Hot Topic Roundtables</td>
</tr>
<tr>
<td>Monday</td>
<td>3:00 p.m.–4:00 p.m.</td>
<td>Exhibitor Networking Break in Exhibit Hall</td>
</tr>
<tr>
<td>Monday</td>
<td>3:00 p.m.–4:00 p.m.</td>
<td>Poster Author Session—Author(s) presentation including Q&amp;A</td>
</tr>
<tr>
<td>Monday</td>
<td>4:00 p.m.–5:30 p.m.</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td>Monday</td>
<td>6:30 p.m.–8:30 p.m.</td>
<td>Documentary Screening—The Fix: The Healing is Mutual</td>
</tr>
<tr>
<td>Monday</td>
<td>7:00 p.m.–8:30 p.m.</td>
<td>Methadone Anonymous Meeting (Open)</td>
</tr>
<tr>
<td>Tuesday, March 31</td>
<td>7:30 a.m.–3:30 p.m.</td>
<td>Registration Open</td>
</tr>
<tr>
<td>Tuesday</td>
<td>7:30 a.m.–8:30 a.m.</td>
<td>Continental Breakfast in Exhibit Hall</td>
</tr>
<tr>
<td>Tuesday</td>
<td>7:30 a.m.–1:30 p.m.</td>
<td>Exhibits</td>
</tr>
<tr>
<td>Tuesday</td>
<td>7:30 a.m.–1:30 p.m.</td>
<td>Posters in Grand Hall</td>
</tr>
<tr>
<td>Tuesday</td>
<td>8:45 a.m.–10:15 a.m.</td>
<td>Middle Plenary Session—Addressing a Public Health Crisis: Opioid Dependence</td>
</tr>
<tr>
<td>Tuesday</td>
<td>10:30 a.m.–12:00 p.m.</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td>Tuesday</td>
<td>12:00 p.m.–1:30 p.m.</td>
<td>Lunch (on your own)</td>
</tr>
<tr>
<td>Tuesday</td>
<td>1:30 p.m.–3:00 p.m.</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td>Tuesday</td>
<td>3:15 p.m.–4:45 p.m.</td>
<td>International Presentations – new session for 2015</td>
</tr>
<tr>
<td>Tuesday</td>
<td>7:00 p.m.–9:30 p.m.</td>
<td>Awards Banquet</td>
</tr>
<tr>
<td>Tuesday</td>
<td>9:30 p.m.–10:30 p.m.</td>
<td>Methadone Anonymous Meeting (Open)</td>
</tr>
<tr>
<td>Wednesday, April 1</td>
<td>7:30 a.m.–1:00 p.m.</td>
<td>Registration Open</td>
</tr>
<tr>
<td>Wednesday</td>
<td>7:30 a.m.–8:00 a.m.</td>
<td>Continental Breakfast</td>
</tr>
<tr>
<td>Wednesday</td>
<td>8:00 a.m.–9:30 a.m.</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td>Wednesday</td>
<td>9:45 a.m.–11:15 a.m.</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td>Wednesday</td>
<td>11:30 a.m.–12:45 p.m.</td>
<td>Closing Plenary Session—The Federal Response to the Opioid Dependence Crisis</td>
</tr>
<tr>
<td>Wednesday</td>
<td>1:00 p.m.–3:30 p.m.</td>
<td>Clinic Tours (Sign-Up at Hospitality Table)</td>
</tr>
</tbody>
</table>
The Certified Medication Assisted Treatment Advocate (CMA) Training Course

8:00 a.m.–5:00 p.m.

The Learning Center

Walter Ginter, CMA, NAMA Recovery, New York, NY
Roxanne Baker, CMA, NAMA Recovery, New York, NY
Laura McNicholas, MD, University of Pennsylvania, Philadelphia, PA
Claude Hopkins, CADC, NAMA Recovery, New York, NY
Cheryl Blankenship Kupras, LCSW, Santa Clara County DADSAMT Program, San Jose, CA
Joycelyn Woods, MA, NAMA Recovery, New York, NY
Herman Joseph, PhD, NAMA Recovery, New York, NY
Wilma Townsend, MSW, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
Vonnshuri S. Wrighten, M.Div., Georgia Department of Behavioral Health and Developmental Disabilities, Atlanta, GA

The leading advocate and recovery organization for medication assisted treatment, the National Alliance for Medication Assisted Treatment (NAMA Recovery), developed this training, believing that professionals, patients, and their families can work together for a better understanding of the physiology of addiction and the use of medication assisted treatment (MAT). Both patients and non-patients are encouraged to become Certified Medication Assisted Treatment Advocates (CMA).

The course presentation includes:

Medication Assisted Treatment – Basic clinical information about medication assisted treatment.

Addiction and Methadone – Current science about addiction in a language understandable to the non-clinician.

Regulations and Accreditation – Current regulations explained by the federal agency that oversees medication assisted treatment, and the State Opioid Treatment Authority.

Hands On Advocacy – Basic tools for advocacy, managing simple issues that confront advocates, educating patients about their rights, handling grievances, legal issues, and working within communities to benefit patients and treatment.

Break Out/Creating Goals – Participate in breakout sessions to strategize the effective ways of communicating information (research findings, new initiatives, support groups) via the Internet, OTPs, community, etc.

Certified Medication Assisted Treatment Advocate (CMA) – Role of a CMA, ethics of advocacy, the mechanism of certification, and professionalize those committed to advocacy.

Participants will gain the initial tools for basic advocacy in order to grow and develop into successful advocates. The course involves eight hours of rigorous training and fulfills the training requirement for Certification as a Medication Assisted Treatment Advocate (CMA).

Pre-Conference Sessions

Saturday, March 28, 2015

8:00 a.m.–5:30 p.m.

Buprenorphine for the Treatment of Opioid Dependence in Office-Based Treatment and Opioid Treatment Programs

Centennial II

John A. Renner, Jr., MD, Boston University School of Medicine, Education Section Veterans Administration Outpatient Clinic, Boston, MA
Laura McNicholas, MD, Philadelphia Veterans Administration Medical Center, Philadelphia, PA
Kenneth Stoller, MD, Johns Hopkins Broadway Center for Addiction, Baltimore, MD

The “Drug Addiction Treatment Act of 2000” created the opportunity to expand treatment for opioid dependence into the mainstream of medical practice, increase the number of persons treated, and have an important positive public health impact. The legislation specifies several ways in which physicians can be considered qualified to prescribe and dispense buprenorphine in their offices for the treatment of opioid dependence. The completion of this training fulfills the requirement prior to notifying the U.S. Department of Health and Human Services (DHHS) of their intention to begin prescribing buprenorphine for the treatment of opioid dependence.

The presentation is designed to train qualified physicians in dispensing or prescribing specifically approved Schedule III, IV, and V narcotic medications for the treatment of opioid addiction in an office-based setting. The goal of this training is to acquire the knowledge and skills needed to provide optimal care to opioid dependent patients by providing: 1) an overview of opioid dependence, 2) the efficacy and safety of buprenorphine, 3) process of patient selection, 4) clinical use of buprenorphine, 5) nonpharmacological interventions, 6) medical psychiatric conditions in opioid dependent patients, 7) office procedures, and 8) special treatment population.

Designated by the DHHS, this training meets the eight-hour requirement and is designed for physicians to dispense buprenorphine in office practice for treatment of opioid dependence. Participation in this training will provide physicians with a comprehensive overview of buprenorphine prescribing and its safe and effective use in an office-based setting. This training is designed for physicians and other primary care providers who are likely to treat opioid dependent persons in their practice, such as those in family practice,
Pre-Conference Sessions

Saturday, March 28, 2015

general internal medicine, psychiatry, pediatrics, adolescent medicine specialists, and Opioid Treatment Programs.

Funding for this course was made possible (in part) by H79T1022022 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

American Academy of Addiction Psychiatry designates this live activity for a maximum of 8 (eight) AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Upon completion of this session, you will be able to understand and use:

- Initial treatment screening, admission procedures, and assessment techniques
- Methadone, buprenorphine, and naltrexone pharmacology, and clinical pharmacotherapy
- Drug testing as a tool
- Information about co-occurring medical disorders
- Information about co-occurring psychiatric disorders
- Knowledge about polysubstance use
- Medication assisted treatment for women with opioid addiction during pregnancy

Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA)

1:00 p.m.–4:00 p.m.

Nurses and Opioid Treatment Programs

Regency V

Linda Burhans, PhD, North Carolina Board of Nursing, Wilson, NC

The team providing patient care at an Opioid Treatment Program (OTP) is typically composed of a variety of professionals fulfilling different roles. Nurses in OTPs conduct assessments, evaluations, render professional judgment, implement physician orders, administer medication, and participate on a multi-disciplinary team for obtaining desired patient outcomes.

Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA)

1:00 p.m.–5:00 p.m.

Countering Opioid Stigma: Communicating Messages to Influence Public Perception

Grand Hall East C

Frank J. Carrillo, BS, ECG, Inc., Englewood, NJ

Opioid Treatment Programs and patients have historically been the target of negative public opinion and adverse media coverage. This has affected our ability to effectively influence national drug policy, explain the science of opioid addiction and treatment, gain the funding necessary to provide quality treatment to those who require it, and ultimately operate in the best interests of our patients and communities.

9:00 a.m.–12:00 p.m.

Opioid Dependence in Peri-Partum Women: Policy, Collaboration, and Strategy

Regency V

Nancy K. Young, PhD, National Center on Substance Abuse and Child Welfare, Lake Forest, CA

Sally Borden, MEd., Kid Safe Collaborative, Inc., Burlington, VT

This session will discuss policy and practice considerations for collaborative practice in working with opioid dependent pregnant and parenting women. The presenters will discuss the newly published guidance document, Medication Assisted Treatment for Pregnant Women with Opiate Dependence. In addition, the session will examine the unique challenges of serving pregnant/postpartum women as it relates to opioid addiction and treatment. Finally, the session will explore the different approaches that SAMHSA’s Pregnant and Postpartum Women grantees use to manage and support integrated care for patients with opioid dependency through medication assisted treatment.

Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA)

9:00 a.m.–5:00 p.m.

Opioid Treatment Program Clinical Staff Education: The Use of Approved Medications in Medication Assisted Treatment

Regency VI

Valentin Bonilla, PA, Beth Israel Hospital, New York, NY

Carolyn Baird, DNP, Waynesburg University, McMurray, PA

The purpose of this presentation is to provide physicians, physician assistants, nurse practitioners, nurses, counselors, social workers, and program administrators with information about medication assisted treatment for opioid addiction including the use of methadone, buprenorphine and naltrexone.
Pre-Conference Sessions

Sunday, March 29, 2015

8:00 a.m.–5:30 p.m.

Opioid Maintenance Pharmacotherapy: A Course for Clinicians

Regency VI

Laura McNicholas, MD, Philadelphia Veterans Administration Medical Center, Philadelphia, PA
Susan Neshin, MD, JSAS Healthcare, Inc., Neptune, NJ
Abigail Kay, MD, Thomas Jefferson University, Philadelphia, PA
Laura Murray, DO, NHS Human Services, Philadelphia, PA

This course is recommended for clinicians who have an interest in increasing their knowledge of medication assisted treatment (MAT) for opioid dependence. The updated curriculum includes current consensus guidance for best practice treatment for opioid addiction, focusing primarily on utilization of methadone.

Topics include overview of opioid dependence, epidemiology, opioid pharmacology, evidence-based treatment options, patient assessment/selection, special populations, induction and maintenance protocols, pain management, drug-to-drug interactions, adverse effects, methadone deaths, managing medical/psychiatric problems, drug testing, regulatory issues, an accreditation update, risk management, and an overview of other medication modalities.

While the course is primarily intended for clinicians with limited experience in MAT, it also provides updated information for more experienced clinicians. Participants will receive a comprehensive syllabus with reference and resource materials. To further integrate the educational objectives, participants are encouraged to discuss challenging problems and clinical issues to facilitate understanding of didactic principles.

The $235.00 registration fee includes course materials, morning coffee service, and afternoon luncheon.

Sponsored by the American Association for the Treatment of Opioid Dependence, Inc. (AATOD)
Supported by the National Institute on Drug Abuse (NIDA)
Supported by Mallinckrodt Pharmaceuticals

1:00 p.m.–5:00 p.m.

New & Emerging Medications for Treating Opioid Use Disorder

Grand Hall East D

Michele Rankin, PhD, National Institute on Drug Abuse (NIDA), Bethesda, MD
Charles P. O’Brien, MD, University of Pennsylvania, Philadelphia, PA
Maria A. Sullivan, MD, Columbia University, New York, NY
William Morrone, DO, Synergy Medical Education Alliance, Saginaw, MI

Injectable naltrexone is a relatively new medication to prevent opioid misuse relapse. Naltrexone is a long-acting opioid antagonist with a high affinity for the mu-opioid receptor. Maintenance therapy with naltrexone has been strongly associated with extremely motivated patients or use in controlled settings. Moreover, additional medications and formulations of currently approved medications are under development for the treatment of opioid dependence.

With the rise in prescription opioid abuse and the transition of these patients to heroin, the co-prescribing of naloxone is increasing in popularity. This session highlights medications for treating opioid dependence and overdose and non-opioid pharmacotherapy options that can be used in Opioid Treatment Programs.

Sponsored by the National Institute on Drug Abuse (NIDA) and the Substance Abuse and Mental Health Services Administration (SAMHSA)

Supported by Addiction Treatment Providers Insurance Program
associated with medical and psychological comorbidity and distress. Rupp and Delaney (2004) shows that patients with substance use disorders (SUDs) are less likely than others to receive effective pain treatment as clinicians are concerned that they may misuse opioids.

The research evidence and clinical experience on how to treat comorbid opioid addiction and pain is emerging. Chang and Compton (2013) described that the goal of chronic pain treatment in patients with SUDs should be the same as that for patients without SUDs, which is to maximize functionality while providing adequate pain relief. However, the complex relationship between pain and addiction requires careful assessment, sustained monitoring, and integrated relapse prevention and pain management in patients treated with methadone, buprenorphine, or naltrexone.

This session will summarize the current research base for the treatment of pain in OTP patients, present assessment and treatment strategies, and specific interventions that have demonstrated its effectiveness.

Sponsored by the National Institute for Drug Abuse, the National Drug Abuse Treatment Clinical Trials Network (NIDA/CTN)

8:30 a.m.–5:30 p.m.

State Opioid Treatment Authorities’ Meeting

Closed Session for State and Federal Officials

Learning Center

PARTICIPANTS:

Robert Lubran, MPA, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
Melinda Campopiano, MD, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
Wilma Townsend, MSW, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
Brandon Johnson, PhD(c), Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
Mary Lou Ojeda, MS, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
Jinhee Lee, PharmD, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
Steve Mason, MSW, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
Tony Campbell, DO, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
Cathy Gallagher, Drug Enforcement Administration (DEA), Crystal City, VA

State Opioid Treatment Authorities

Federal officials, including Substance Abuse and Mental Health Services Administration/Center for Substance Abuse Treatment (SAMHSA/CSAT) staff and State Opioid Treatment Authorities, will convene to share information and discuss a variety of topics of
interest to both SAMHSA and the States. Issues of mutual concern in the approval and monitoring of Opioid Treatment Programs, including clinical, administrative, financing, and regulatory policy topics, will be discussed to improve and coordinate joint oversight.

Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA)

9:00 a.m.–12:00 p.m.

Opioid Treatment Program Accreditation Town Hall Meeting

Centennial I

Megan Marx, MPA, The Joint Commission, Oakbrook Terrace, IL

This session is designed to be an open forum for Joint Commission accredited programs. It is an opportunity for accredited programs to learn about recent and upcoming standards revisions and to discuss how to achieve standards compliance. Topics expected to be reviewed include: “Behavioral Health Home Certification—One Year Later”; “Roadmap to Accreditation—Staying on the Path to Success”; “Strategies for a Successful Accreditation Survey”; “Overcoming Challenges to Person Centered Care, Treatment or Service Planning”; “Accreditation Standards Top Compliance Challenges for 2014”; and “Strategies to Address Human Resource/Staffing Challenges.” This session will also include an overview of the revised Federal Guidelines for Opioid Treatment Programs with a focus on how the revised guidelines will affect accreditation standards. (Note: Pending the release of the revised federal guidelines.)

Registration for this session is open to all Joint Commission accredited Opioid Treatment Programs.

Sponsored by The Joint Commission

9:00 a.m.–12:00 p.m.

Recovery and Medication Assisted Treatment

Centennial II

Wilma Townsend, MSW, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD

Walter Ginter, CMA, Medication-Assisted Recovery Supports (MARS) Project, New York, NY

Kelly Moehling, CRC Health Group, Portland, OR

Erika Helmerichs, CRC Health Group, Portland, OR

Recovery has been defined by the Substance Abuse and Mental Health Services Administration (SAMHSA) as, “A process of change through which individuals improve their health and wellness, live a self-directed life, and strive to reach their full potential.” SAMHSA has also identified four major dimensions that support a life in recovery: Health, Home, Purpose, and Community. Receiving medication assisted treatment is one part of a person’s recovery process. It is important for people to learn about all aspects of recovery from taking medication to the inclusion of health, home, purpose, and community. This session will help organizations understand the recovery process for individuals receiving medication assisted treatment and how they can assist individuals in their recovery process.

Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA)

1:00 p.m.–4:00 p.m.

Managing Workplace Risks: 10 Things Employers Need to Know

Regency VII

Emily S. Borna, Esq, Jackson Lewis P.C., Atlanta, GA

Kathryn J. Russo, Esq, Jackson Lewis P.C., Melville, NY

Looking ahead in 2015, savvy employers and employees are paying close attention to the current hot-button labor and employment law issues including: aggressive federal agencies; rampant state legislation; social media; criminal background checks; crisis management; FMLA expansion (sexual assault, domestic violence, stalking); enhanced pregnancy protections; transgendered employees; continuation of the misclassification campaign; and supreme court decisions.

Employment law challenges present risks and often divert attention from other important business matters. Staying on top of the latest developments and looking ahead is essential to avoiding the courthouse.

This session will break down the top workplace legal developments at this juncture and explain how recent regulatory changes and state and federal case holdings affect your workforce. This session will also address some best practices recommended for employers to take for compliance and explore ways employers may avoid liability with preventive strategies.

Sponsored by the American Association for the Treatment of Opioid Dependence, Inc. (AATOD)
Pre-Conference Sessions

Sunday, March 29, 2015

1:00 p.m.–4:00 p.m.

**OTP Liability for Patient-Related Motor Vehicle Accidents: A Mock Trial and Focus Group Presentation**

Centennial I

*James A. Bello, Esq. Morrison Mahoney, Boston, MA*
*Noel Dumas, Esq. Morrison Mahoney, Boston, MA*

The objective of this session is to highlight the risk of Opioid Treatment Program (OTP) liability for patients and third parties who are injured in vehicular accidents arising out of the negligent administration of methadone and/or inadequate counseling or monitoring of continuous illicit drug use. The Mock Trial and Focus Group Presentation are premised upon an actual case brought by an injured patient against an OTP.

Conference participants will be presented with the closing arguments of counsel. The plaintiff’s (injured party) case focuses on “profits over people.” The plaintiff alleges that the clinic failed to implement any meaningful consequences in response to the patient’s continued use of illicit drugs, specifically benzodiazepines. Plaintiff contends that if she was faced with consequences for continued drug use, she would have stopped using benzodiazepines, and the accident would not have occurred. The plaintiff’s case highlights the legal consequences of violating company policies, state regulations and industry standards, and the legal implications of such violations in a court of law.

The defense of the clinic focuses upon the concept of harm reduction and personal responsibility. Despite continuous positive drug screens, the patient made significant progress in the program, with periods of complete abstinence. The defense contends that the clinic cannot be held responsible for the poor decisions of a fully informed, consenting adult. There is also emphasis on the absence of legal “causation”; i.e. evidence that had the consequences been attempted, the patient would have stopped using illicit drugs (and the accident would have been avoided).

The teaching session will focus on the importance of adequate documentation and compliance with policies and regulations. The presenters will show actual video clips from mock trial jury deliberations, which reveal laypersons’ thoughts on methadone treatment, the OTP industry, and drug addiction in general.

*Sponsored by the American Association for the Treatment of Opioid Dependence, Inc. (AATOD)*

---

1:00 p.m.–5:00 p.m.

**Presentations by the World Federation for the Treatment of Opioid Dependence (WFTOD)**

**Hanover CD**

The World Federation for the Treatment of Opioid Dependence (WFTOD) was founded during the European Opiate Addiction Treatment Association (EUROPAD) meeting of July 2007 in Ljubljana, Slovenia. All of the member nations, which included the member countries of EUROPAD and all of the member states within AATOD, agreed to a charter for the World Federation.

**CHAIRMAN:** Icro Maremmani, MD, Santa Chiara University Hospital, Pisa, Italy

**INTRODUCTIONS:** Michael Rizzi, AATOD International Committee Chair, Cranston, RI

**1:00 p.m.–1:20 p.m.**

The Misuse: A Part of Opioid Maintenance Treatment

*SPEAKER:* Alice Deschenau, MD, What’s Up Doc, Villejuif, France
*A. Deschenau, D. Touzeau* (Villejuif, France, EU)

**1:20 p.m.–1:40 p.m.**

Measuring Outcomes in Opioid Dependence Care: Expert Consensus on Need for Improved Outcome Measurement Tools

*SPEAKER:* Icro Maremmani, MD, Santa Chiara University Hospital, Pisa, Italy
*I. Maremmani* (Pisa, Italy, EU), *H. Alho* (Helsinki, Finland, EU), *R. Littlewood* (London, UK)

**1:40 p.m.–2:00 p.m.**

Agonist Opioid Treatment and Sexual Dysfunctions

*SPEAKER:* Lorenzo Somaini, MD, Addiction Treatment Center, Biella, Italy
*L. Somaini* (Biella, Italy, EU)

**2:00 p.m.–2:20 p.m.**

Replacement Therapy Method Resettlement in Prisons–Yes or No?

*SPEAKER:* Samir Kasper, MD, Cantonal Institute for Addiction Zenica, Bosnia & Erzegovina
*S. Kasper, J. Sofic*, *H. R. Awad* (Zenica, Bosnia & Erzegovina)

**2:20 p.m.–2:40 p.m.**

Emerging Trends in Alternative Routes Reported for Prescription Drug Misuse: An International Perspective

*SPEAKER:* Jody L. Green, PhD, Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS® System), Denver, CO
*J. Green* (Denver, CO, USA)
2:40 p.m.–3:00 p.m.
Motivational Interviewing to Facilitate 12 Steps for Opiate Addiction

**SPEAKER:** Stephen R. Andrew, LCSW, Health Education and Training Institute, Portland, ME

S. R. Andrew (Portland, ME, USA)

3:00 p.m.–3:20 p.m.
Treatment of Chronic Hepatitis C in Drug Users: Ethical, Successful, and Useful

**SPEAKERS:**
André-Jean Remy, MD and Hugues Wenger, MD, Centre Hospitalier de Perpignan, France
A.J. Remy, H. Wenger, H. Bouchkira* (Perpignan, France, EU)

3:20 p.m.–3:40 p.m.
Factors Associated with Outcome of Inpatient Opioid Addiction Treatment

**SPEAKER:** Mirjana Delic, MD, Center for Treatment of Drug Addiction, University Psychiatric Clinic Ljubljana, Slovenia
M. Delic, L. Lusa*, P. Pregelj* (Ljubljana, Slovenia, EU)

3:40 p.m.–4:00 p.m.
Risk Factors for Weight Gain during Methadone Maintenance Treatment

**SPEAKER:** Einat Peles, PhD, Dr. Miriam & Sheldon G. Adelson Clinic for Drug Abuse, Treatment & Research, Tel Aviv, Israel
E. Peles, S. Schreiber*, A. Sason*, M. Adelson* (Tel Aviv, Israel)

4:00 p.m.–4:20 p.m.
Introducing a Naloxone Nasal-Spray Project as Part of a National Overdose Prevention Campaign in Norway: First Experiences and Results

**SPEAKER:** Thomas Clausen, MD, Norwegian Centre for Addiction Research, University of Oslo, Norway
T. Clausen (Oslo, Norway)

4:20 p.m.–4:40 p.m.
Effectiveness of Medication-Assisted Treatment with Methadone, Buprenorphine, and Sustained Release Morphine

**SPEAKER:**Andrej Kastelic, MD, Center for Treatment of Drug Addiction, Ljubljana, Slovenia
A. Kastelic (Ljubljana, Slovenia EU)

4:40 p.m.–5:00 p.m.
Questions & Answers

* Contributed to research but will not be presenting.

**Sponsored by the American Association for the Treatment of Opioid Dependence, Inc. (AATOD), EUROPAD, and the World Federation for the Treatment of Opioid Dependence (WFTOD)**

1:00 p.m.–5:00 p.m.

**Overdose Prevention Implementation Strategies**

**Centennial II**

*Sharon Stancliff, MD, Harm Reduction Coalition, New York, NY*
*Reverend Fred Wells Brason II, President/CEO, Project Lazarus, and Project Director, Community Care of North Carolina’s Medicaid Management System Statewide Chronic Pain Initiative, Moravian Falls, NC*
*Pam Lynch, LLMSW, WhoSoEver Collaborative, Traverse City, MI*

There have been significant increases in overdose deaths related to prescription drug misuse and illicit heroin in the past 10 years. Thus, there is a significant need for both systemic and individual interventions for healthcare professionals and first responders to address opioid overdoses.

This session will cover Overdose Prevention Programs that include the distribution of naloxone, training of non-healthcare first responders, and the current evidence for bystander administration of naloxone to reverse opioid overdoses.

**Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA)**

---

**Welcome Reception**

Sunday, March 29 | 5:30 p.m. –7:30 p.m.

**Exhibit Hall**

The Welcome Reception affords all participants the opportunity to make new professional and personal acquaintances, as well as enjoy some relaxing time with old friends and colleagues not seen for too long.

**Sponsored in part by Atlantic Diagnostic Laboratories and Orexo**

---

**March 28–April 1, 2015 | Atlanta, Georgia**
Exhibit Hall

The AATOD Conference serves as a central gathering point for the opioid treatment community and offers significant opportunities for exhibiting companies and attendees to interact with other professionals who are devoted to the treatment of opioid dependence throughout the nation and abroad. The registrants will consist of the decision makers in this field who spend over $1 billion annually treating more than 325,000 patients in Opioid Treatment Programs. In order to provide exhibitors with steady exposure to conference attendees, all continental breakfasts and refreshment breaks will be held exclusively in the exhibit area. An Exhibitor’s Networking Event will be held Monday, March 30th to encourage contact and dialogue between opioid treatment professionals and the exhibiting companies.

EXHIBIT HOURS

Sunday, March 29  4:00–7:30 p.m.
Monday, March 30  7:30–9:30 a.m.; 11:30 a.m.–4:30 p.m.
Tuesday, March 31  7:30 a.m.–1:30 p.m.

POSTER AUTHOR SESSIONS

Posters are in place at all times when the Grand Hall is open. Authors will present their topic on Monday, March 30, from 7:30 a.m.–8:45 a.m. and 3:00 p.m.–4:00 p.m.

The following domestic and international posters will provide valuable research findings to treatment providers.

1. It Ain’t Me: Reducing the Impact of Implicit and Unconscious Provider Bias on OTP Patients
   James Anderson, PA-C

2. The Methadone Education Project: Providing Resources for Community Providers
   James Anderson, PA-C

3. Cannabis—The Anti-Gateway Drug
   Angela Bonaquidi, LCSW

4. Utilization of Telemedicine to Treat Hepatitis C at a Medication-Assisted Opioid Treatment Program
   Lawrence Brown, Jr., MD

5. Smoking or not Smoking Buprenorphine
   Alice Deschenau, MD

6. Integrating Horticulture Therapy into an Opioid Treatment Program and Other Service Models
   Kathryn Eggert, LCSW

7. Integrating Overdose Prevention into an Opioid Treatment Program
   Scott Farnum, PhD(c)

8. How Strong is the Relationship Between Methadone Dose and QTc Interval?
   Scot Fleshman, MSN

9. Reductions in Prescription Opioid Abuse among Enrollees into Opioid Treatment Programs
   Chunki Fong, MS

10. Improving Self-Esteem Among Opiate Addicted Patients on MAT: A Six-Week Intervention
    Bonnie Franckowiak, DNP

11. Integrating an Opioid Treatment Program into a Correctional Facility
    Robert Freeman, BS

12. The Effects of Mothers’ Addiction and Substance Abuse on their Infants
    Hamideh Jahangiri, MD

13. Pattern and Intensity of Smoking and Alcohol Drinking in Adolescents
    Hamideh Jahangiri, MD

14. CBT Effect to Reduce Nicotine Dependence in Heavy Smoker Patients with Hypertension
    Hamideh Jahangiri, MD

15. Integrated Care: Mental Health and MAT
    Evan Kletter, PhD

16. Primary Care Integration
    Michelle Kletter, BA

17. Age and Gender Distribution among Patients Entering Treatment for Opioid Addiction
    Sarah Lavery, BS

18. Utilization of an Electronic Information System to Evaluate Practice at a Medication Assisted OTP
    Steven Kritz, MD

Trivia! Please visit the Exhibit Hall and answer questions to enter a drawing for prizes from AATOD at the Closing Plenary Session. See insert in your registration materials for additional information.
19. Community Based Overdose Prevention – Providing Naloxone in Methadone Maintenance Programming
Deborah Malatesta, LCSW

20. Challenges to Opioid Treatment Providers after Hurricane Sandy: Impact, Preparedness, and Recovery
Harlan Matusow, PhD

21. The Association of PHQ-9 & MDQ Scores with Lifetime Suicide Ideation & Attempt among Ageing Opioid-Dependent Individuals
Mary Mbabba, MPH

22. Decisions in Recovery: A Web-Based Shared Decision Making Tool for Medication-Assisted Treatment
Niki Miller, MS

23. Prevalence of Substance Abuse Among University Students
Alireza Norouzi, PhD

24. Opioid Addiction and Regulated Substitution
Bengt Eide Olsen

25. Self-Reported Overdose Risks in a Sample of Patients Enrolled in an Opioid Treatment Program
K. Michelle Peavy, PhD

26. Risk Factor for Weight Gain during Methadone Maintenance Treatment
Einat Peles, PhD

27. Treatment of Chronic Hepatitis C in Drug Users: Ethical, Successful, and Useful
Andre Jean Remy, MD

28. Use of Opiates to Get High in Patients Seeking Replacement Therapy: Europe and the United States
Lorenzo Somaini, MD

29. Policy Considerations and Collaborative Partnerships: Working with Opioid Dependent Pregnant and Parenting Women
Nancy Young, PhD

30. Effects of Buprenorphine/Naloxone Dosing in Opioid-Dependent Medicaid Patients
Vladimir Zah, PhD(c)

31. Analysis of the ‘Revolving Door’ Effect in Opioid Dependent Patients from Medicaid Insurance Claims
Vladimir Zah, PhD(c)

**Conference Sessions**

**Monday, March 30, 2015**

**CONTINENTAL BREAKFAST**
Monday, March 30 | 7:30 a.m.–8:30 a.m.
Grand Hall West
Sponsored by VistaPharm Inc.

8:45 a.m.–10:15 a.m.

**OPENING PLENARY SESSION**

**Challenges and Opportunities to Impact the Opioid Dependence Crisis**

Centennial III & IV

- **Jonathan P. Connell, MA, Conference Chair**
  President, Private Clinics, and TLC Clinic, Albany, GA

- **Frank W. Berry, III, Commissioner, Department of Behavioral Health and Developmental Disabilities (DBHDD), Atlanta, GA**

- **Mark W. Parrino, MPA, President, American Association for the Treatment of Opioid Dependence, Inc. (AATOD), New York, NY**

- **Merrill Norton, PharmD, Clinical Associate Professor, University of Georgia, Athens, GA**

As opioid dependence becomes part of the national and international conversation, the Opening Plenary Session will review AATOD’s projects and efforts in the Southeast and around the world to expand knowledge of and decrease stigma of medication assisted treatment. Jonathan P. Connell will welcome the attendees and provide an overview of this exciting conference. Mr. Connell will be followed by a very special welcome to Georgia by Frank W. Berry, Commissioner of Georgia’s Department of Behavioral Health and Developmental Disabilities. Mr. Mark Parrino, AATOD President, will provide an overview of the challenges, opportunities, and accomplishments of AATOD. Dr. Merrill Norton will provide the closing remarks and present information regarding nationwide and state efforts to address opioid dependence from a pharmacy/pharmacist perspective. Dr. Norton will also explore efforts to coordinate care and reduce the escalation of addiction from the perspective of a pharmacist and educator.
Conference Sessions

Monday, March 30, 2015

10:30 a.m.–12:00 p.m.

WORKSHOP SESSIONS

Workshops will offer a chance to review the latest treatment data and healthcare policies, examine their implications for our patients, and strengthen the skills needed to improve the quality of services.

**BASIC TRACK:** We offer a special sequence of workshops designed to act as a refresher for seasoned professionals and to meet the needs of individuals who are new to this field. Those who attend all six sessions listed will receive a special certificate of completion.

*Basic Track Workshop Sessions: A1, B1, C1, D1, E1 and F1*

**A1 Methadone 101**

Regency VI

Laura F. McNicholas, MD, University of Pennsylvania, Philadelphia, PA

Methadone maintenance treatment has been available for decades; yet many clinicians do not understand how and why it is effective in treating opioid dependence and addiction. The presenter will review the basic elements of opioid agonist treatment; examine the pharmacologic aspects of methadone; present initial screening, admission procedures, and assessment techniques; describe associated medical, psychiatric, and substance abuse conditions associated with opioid addiction; evaluate the efficacy of methadone therapy; and review other opioid agonist treatments.

*Basic Track*

**A2 Rhode Island OTP Health Homes: Making a Difference in Patients’ Lives**

Centennial I

Linda Hurley, MA, CODAC Behavioral Healthcare Inc., Cranston, RI
Susan A. Storti, PhD, Rhode Island Opioid Treatment Program Health Home Initiative, Warwick, RI
Peter Morris, BS, Discovery House/Smart Management Inc., Providence, RI

In 2013, Centers for Medicare & Medicaid Services (CMS) approved a State Plan Amendment, submitted by the State of Rhode Island, to implement Health Homes within Opioid Treatment Programs (OTPs). This workshop will provide a comprehensive overview of the ongoing implementation of this statewide service delivery model. Initial planning, implementation guidelines, and data collection methods will be discussed. Presenters will also describe successful outreach methods which have resulted in new or strengthened collaborations with the medical community, legal and corrections community, housing resources, and employment providers. Patient engagement and workforce development strategies will be shared in addition to a comprehensive overview of revenue and costs.

**A3 Mindfulness-Based Parenting for Mothers in Drug Treatment**

Centennial II

Diane Abatemarco, PhD, Nemours duPont Pediatrics, Philadelphia, PA
Wendy Weingarten, MSW, Thomas Jefferson University, Philadelphia, PA
Karol Kaltenbach, PhD, Thomas Jefferson University, Philadelphia, PA

Practicing Safety Mindfulness Project for Mothers in Drug Treatment is an innovative intervention project intended to improve parenting responsiveness in mothers receiving treatment for opioid dependence by implementing Mindfulness-Based Parenting (MBP), enhanced pediatric care, and case management. This workshop will provide hands on skill-learning by sharing the experience of development and implementation. Topics of discussion will include: comprehensive curriculum adaptation, planning, and reiteration that include conducting interviews with key personnel/stakeholders; reviewing state-of-the-art substance use treatment guidelines; developing mother/baby dyad education; and informing the program with the impact of trauma. Presenters will discuss the rationale for using MBP as a foundation for parenting intervention.

**A4 Marijuana and Medication Assisted Treatment**

Centennial III & IV

Anthony Campbell, DO, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
Katherine Cuoto, LADC, Maine Office of Substance Abuse and Mental Health Services, Augusta, ME
Ron Jackson, LICSW, University of Washington, Seattle, WA

Marijuana is the most commonly used illicit substance in the United States. This session will provide information on risks associated with marijuana use in patients treated for opioid disorders with opioid therapies. While marijuana is still considered an illegal substance, SAMHSA recognizes that new state policies have resulted in an increased number of patients using marijuana. Additionally, questions have arisen about the potential therapeutic and adverse health effects on patients in Opioid Treatment Programs. This session will examine federal, state, and local program policy implications on the use of marijuana for patients engaged in medication assisted treatment for opioid dependence.

**A5 Health Policy Opportunities & Challenges: Update from Legal Action Center**

Regency VII

Gabrielle de la Gueronniere, JD, Legal Action Center, Washington, DC
Paul Samuels, JD, Legal Action Center, New York, NY

With the implementation of the Affordable Care Act (ACA), millions more Americans have access to quality, affordable health coverage, including coverage for substance use disorders. New initiatives and ongoing challenges impact the future of treatment delivery and financing. These changes have unprecedented implications...
for expanding access to critical drug and alcohol-related services and transforming the treatment delivery system. This workshop will discuss current and future federal developments related to substance use disorder treatment, the future of medication assisted treatment in the new health reform environment, delivery system reforms, and opportunities available for improving federal policy moving forward.

**1:30 p.m.–3:00 p.m.**

**HOT TOPIC ROUNDTABLES**

Hot Topic Roundtables are facilitated discussions that focus on current controversial issues in an informal context. Meet with your colleagues as you learn, challenge, support, and share your views with others who may have similar or different opinions, experiences, or interests.

Experienced leaders in the field will be facilitating these sessions.

**HT1—Confronting Stigma and Misinformation within Methadone Treatment and Beyond**
Hanover AB
FACILITATORS: Robert C. Lambert, MA and Alan Lee Nolan, LCSW

**HT2—Buprenorphine, Methadone, Extended Release Naltrexone: Medication Choice as Collaboration between Patient and Doctor**
Hanover FG
FACILITATOR: Robert Kearney, MD

**HT3—Addressing Stimulant Use in the OTP**
Grand Hall East B
FACILITATOR: Kellie Bollins, PsyD

**HT4—Confidentiality: Balancing Privacy with Informed Care**
Grand Hall East C
FACILITATOR: Karla Lopez, JD

**HT5—Dose Capping: Is It Still Happening Under the Current Federal Regulations?**
Grand Hall East D
FACILITATORS: Zac Talbott, CMA and Bettye Harrison, MSW

---

**WORKSHOP SESSIONS**

**#1 Managing Workplace Risks: Medical Marijuana and Disability-Related Topics**
Centennial I
*Kathryn Russo, JD, Jackson Lewis P.C., Long Island, NY*

This workshop will explore recent legal trends in several disability related topics including: legal and practical issues raised by recent laws permitting medical marijuana and recreational marijuana; current trends in workplace drug and alcohol testing programs and litigation arising out of such testing; balancing the need for a safe workplace environment with an employee’s need to take lawful prescription medications; legal trends in “reasonable accommodations” of employees’ medical conditions; and the EEOC’s new Enforcement Guidance on Pregnancy Discrimination.

**#2 A Practical Approach to Implementing Cardiac Intervention in Opioid Treatment Programs**
Centennial II
*Mori J. Krantz, MD, University of Colorado, Cardiology Division, Denver, CO*
*Ryan Borne, MD, University of Colorado, Cardiology Division, Denver, CO*
*Megan Marx, MPA, Joint Commission, Oakbrook Terrace, IL*

Feedback from physicians attending the AATOD 2013 Cardiac Safety session was unanimous that current guidelines for implementation of cardiac safety programs in methadone maintenance treatment do not provide adequate clarity on clinical action steps. This workshop will present data on three tools that were developed to aid clinicians implementing cardiac safety interventions. The tools were harmonized to be congruent with published guidelines in several domains. Refinement of these tools is ongoing. Evaluation of their utility in practice may provide insights into their efficacy and optimize related accreditation standards.

---

**EXHIBITORS NETWORKING BREAK**

**Monday, March 30 | 3:00 p.m.–4:00 p.m.**

Grand Hall
*Sponsored in part by O.Berk Company of New England and Kols Containers*
Data suggest that prescription drug abuse remains a public health problem with 81% of new heroin initiates indicating prior prescription analgesic misuse. ONDCP’s Prescription Drug Abuse Prevention Plan identifies Prescription Drug Monitoring Programs (PDMPs) as a means to reduce prescription drug misuse and abuse since PDMPs can be used as a clinical decision-making tool to ensure appropriate medication therapy and identify individuals in need of further assessment/treatment. While federal rules currently prohibit Opioid Treatment Programs (OTPs) from transmitting prescription data to PDMPs, OTPs are encouraged to access PDMPs to enhance medication management. Presenters will describe PDMPs, their use in OTPs, and the integration of PDMPs into Health Information Technology (HIT) systems.

**B3 Neurobiological Basis & Interventions: Comorbid Opioid Use Disorder & PTSD**

Centennial III & IV  
Icro Maremmani, MD, Santa Chiara University Hospital, Pisa, Italy  
Ayman Faried, MD, Atlanta Veterans Administration Medical Center, Decatur, GA  
Pamela Eilender, PsyD., Atlanta Veterans Administration Medical Center, Decatur, GA

There is a high comorbidity between post-traumatic stress disorder (PTSD) and substance use disorders (SUD). Self-medication with alcohol and drugs is a common reaction to the physical and psychological impacts of PTSD, which can lead to significant consequences including the development of an opioid use disorder. Brain imaging has been used recently to provide more information about the neurobiological basis for PTSD and opioid use disorder. The neurobiological link, pharmacological interventions, and integrated psychological treatment approaches for comorbid PTSD and SUD will be reviewed.

**B4 Current Issues: From the Viewpoint of the Patient**

Regency VI  
Herman Joseph, PhD, National Drug Research Institute, New York, NY  
Joycelyn Woods, MA, National Alliance for Medication Assisted (NAMA) Recovery, New York, NY  
Brenda Davis, CASAC-T, Beth Israel/Mount Sinai Methadone Maintenance Program, New York, NY

With the ongoing opioid addiction epidemic, programs must gear up for an influx of patients. While prescribing methadone, buprenorphine, or naltrexone is important, it is not enough. Patients have developed their own ideas about addiction and suspicions about treatment. The stigma they experience affects social interactions, programs, and their views about medications. Conveying research findings, regulation, and rights is important if patients are to understand their conditions, succeed in recovery, and eliminate stigma. Certified methadone advocates and enlightened programs will discuss successful methods to assist patients to resolve these and other challenging issues.
B5 Treatment for Youth Opioid Addiction: Pathways to Engagement

Centennial I

Marc Fishman, MD, Maryland Treatment Centers, Baltimore, MD
Ann Bruner, MD, Mountain Manor Treatment Center, Baltimore, MD

The current epidemic of opioid dependence has devastating consequences for youth and their families. Recent findings have supported approaches that combine relapse prevention medications, such as buprenorphine and extended release naltrexone, with psychosocial interventions. However, the field has many questions about the appropriate use of these medications in youth: selecting good candidates, how to choose between treatments, duration of treatment, benchmarks for adequate response, how to improve retention, response to ongoing opioid or non-opioid substance use, response to medication non-compliance, and the appropriate role for families. This workshop will feature presentations to frame the central questions, followed by case-based scenarios with unfolding decision points as a basis for discussion.

6:30 p.m.–8:30 p.m.

Screening of Documentary Film—The Fix: The Healing is Mutual

Centennial II

Sarah Church, PhD, Division of Substance Abuse, Albert Einstein College of Medicine, Bronx, NY
Laura Naylor, By the By Productions, New York, NY
Junior Alcantara, Division of Substance Abuse, Albert Einstein College of Medicine, Bronx, NY

The Fix conveys a message of hope and recovery by telling the stories of successful methadone patients who become Hepatitis C Peer Educators. This film demonstrates methadone treatment as a platform for therapeutic narrative storytelling, innovative group treatment for hepatitis C, and shows the power of peer educators in building an advocacy movement and community within an Opioid Treatment Program (OTP). It was an official selection at AFI Docs 2014, Maine International Film Festival 2014, and winner of the Jury Prize for Best Documentary at SOHO International Film Festival 2014. The documentary will be followed by a panel discussion including question and answer session.

Conference Sessions

Tuesday, March 31, 2015

CONTINENTAL BREAKFAST

Tuesday, March 31 | 7:30 a.m.–8:30 a.m.

Grand Hall West

Sponsored by Reckitt Benckiser Pharmaceuticals, Inc.

MIDDLE PLENARY SESSION

8:45 a.m.–10:15 a.m.

Addressing a Public Health Crisis: Opioid Dependence

Centennial III & IV

MODERATOR:

Kimberly Jeffries Leonard, PhD, Deputy Director, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse and Treatment (SAMHSA/CSAT), Rockville, MD

SPEAKERS:

Richard C. Dart, MD, Director, Rocky Mountain Poison and Drug Center, and Executive Director, Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS® System), Denver, CO
Reverend Fred Wells Brason, II, President/CEO, Project Lazarus, and Project Director, Community Care of North Carolina’s Medicaid Management System Statewide Chronic Pain Initiative, Moravian Falls, NC
Thomas Frieden, MD, Director, Center for Disease Control and Prevention, Atlanta, GA (Conditional Acceptance)

The conference theme “Addressing a Public Health Crisis: Opioid Dependence” will be explored during the themed Middle Plenary. The speakers are leaders within their fields and will discuss how each experiences the opioid dependence crisis and how they work to address the issue. Dr. Kimberly Leonard will moderate the session and provide an update on CSAT’s current efforts in regards to addressing the opioid epidemic. Dr. Richard Dart will discuss current trends in prescription drug abuse research and how current strategies can ensure the safe and proper use of prescription medications. From a different perspective, Reverend Brason will discuss how Project Lazarus efforts have affected the opioid dependence health crisis through opioid prescribing practices, emergency department interventions, treatment provision, and overdose rescue medication provision. The final speaker, Dr. Thomas Frieden, will provide the public health perspective and how this can improve prevention and treatment efforts.
engaged in medication assisted treatment. This workshop will focus on the relationship between pain and opioid dependence and the pathways to addiction care among persons who have previous or ongoing pain. Additionally, findings from a study focused on prescription opioid use for the treatment of pain and engagement in addiction treatment among Medicaid recipients will be presented.

C4 Challenging Punitive State Responses to Opioid Dependence & Treatment

Centennial II
Kylee Sunderlin, JD, National Advocates for Pregnant Women, New York, NY
Karla Lopez, JD, Legal Action Center, New York, NY

Despite medication assisted treatment’s (MAT) well-established value and effectiveness, state actors often refuse to defer to medical judgment. Throughout the country, drug courts, parole and probation departments, and judges frequently prohibit participation in MAT, and individuals who are incarcerated are often denied and forced to detoxify from MAT. Such punitive responses to treatment fly in the face of evidence-based medical care and create dangerous legal precedent. This workshop will discuss relevant legal protections and barriers, as well as ways to challenge the criminal justice and civil child welfare policies that routinely subject people in the United States to unjust, inhumane, and unconstitutional treatment.

C5 Overdose Prevention Updates

Centennial III & IV
Melinda Campopiano, MD, Substance Abuse and Mental Health Service Administration (SAMHSA), Rockville, MD
Reverend Fred Wells Brason, II, Project Lazarus and Community Care of North Carolina’s Medicaid Management System Statewide Chronic Pain Initiative, Moravian Falls, NC
Pamela Lynch, LLM, Northern Lakes Community Mental Health, Traverse City, MI

Community Based Opioid Overdose Prevention Programs that include the distribution of naloxone have increased in response to alarmingly high overdose rates in recent years. The current evidence from non-randomized studies suggests that bystanders (mostly opioid users) can and will use naloxone to reverse opioid overdoses. Opioid overdose prevention treatment programs are well placed to reach potential bystanders and directly assist patients.

10:30 a.m.–12:00 p.m.
WORKSHOP SESSIONS

C1 Building Therapeutic Partnerships: The Most Important Evidence-Based Practice
Regency VI
Robert C. Lambert, MA, Connecticut Counseling Centers, Inc., Norwalk, CT

Research indicates that the quality of the therapeutic relationship has a greater effect on patient retention and outcomes than the specific counseling approach used. This workshop will focus on the opportunities and unique challenges involved in enhancing the therapeutic alliance with medication assisted patients within the clinic setting, a review of the fundamentals of forming and maintaining a therapeutic relationship and the factors that affect the quality of the therapeutic relationship, explore patient expectancy as a therapeutic factor, discuss the use of patient feedback to strengthen the therapeutic alliance, and explore boundary issues specific to the counselor in recovery.

*Basic Track

C2 Prescription Monitoring Among Patients in an OTP: Using the PMP for Good
Regency VII
Robert Roose, MD, Providence Behavioral Health Hospital, Sisters of Providence Health System, Holyoke, MA
Gwen Fenton, RN, Providence Behavioral Health Hospital, Sisters of Providence Health System, Holyoke, MA
Heather Peterson, PA-C, Providence Behavioral Health Hospital, Sisters of Providence Health System, Holyoke, MA

An interactive presentation will be used to discuss the use of statewide Prescription Monitoring Program (PMP) Data to guide Opioid Treatment Program (OTP) best practices. Topics will include the use of PMP Data in OTPs, prevalence of controlled substance prescriptions among patients enrolled in OTPs, clinical follow up, patient education, communication between prescribers, use of benzodiazepines, and chronic use of opiates.

C3 Emerging Pathways for the Diagnosis and Treatment of Persons with Opioid Dependence and Pain
Centennial I
Holly Hills, PhD, University of South Florida, Tampa, FL
Tara Richards, PhD, University of Baltimore, School of Criminal Justice, Baltimore, MD

Non-malignant chronic pain is one of the most pervasive problems faced by medical professionals. As such, questions remain as to whether primary care physicians, or physicians in other medical specialties, identify and diagnose patients who present with opioid dependence, and subsequently, whether these patients become engaged in medication assisted treatment. This workshop will focus on the relationship between pain and opioid dependence and the pathways to addiction care among persons who have previous or ongoing pain. Additionally, findings from a study focused on prescription opioid use for the treatment of pain and engagement in addiction treatment among Medicaid recipients will be presented.
The presenters will discuss different models of overdose prevention education and means of providing naloxone. The focus will be on successful collaborative relationships with Opioid Treatment Programs and strategies for implementing similar models.

1:30 p.m.–3:00 p.m.

WORKSHOP SESSIONS

D1 Recovery Coaching in OTPs

Centennial II

Walter Ginter, CMA, Medication-Assisted Recovery Supports (MARS) Project, Bronx, NY
Suzanne Hall-Westcott, MS, Beyond MARS Training Institute, Bronx, NY
John Coppola, MSW, New York Association of Alcoholism and Substance Abuse, Bronx, NY

This presentation will provide an overview of what Recovery Coaching is (with acknowledgement of other similar terminology that is used for peer-to-peer services), as well as what training and implementation concerns need to be addressed. There will also be a discussion of outcome data in support of peer recovery services as well as anecdotal evidence in support of implementation efforts for recovery coaching by sharing the MARS experience of instituting Recovery Coaching in a medication assisted treatment environment. In addition, the guidelines and issues around the credentialing of Recovery Coaches will be discussed.

*D Basic Track

D2 Health Reform and Access to Opioid Treatment Medications: Early Findings

Regency VI

Sharon Reif, PhD, Brandeis University, Waltham, MA
Cynthia Campbell, PhD, Kaiser Permanente, Oakland, CA
Traci Rieckmann, PhD, Oregon Health & Science University, Portland, OR

Researchers will present recent findings from three ongoing studies examining various aspects of access to opioid treatment medications pre and post health reform. The first examines changes in the management of access to methadone, buprenorphine, and extended release naltrexone using data from a nationally representative survey of health plans. The second examines changes in the utilization of buprenorphine in specialty treatment within a large, private, integrated healthcare delivery system. The third examines strategies related to the provision of methadone, buprenorphine, and extended-release naltrexone in Oregon’s Medicaid Coordinated Care Organizations. Findings provide insights into the promise and challenges of this coverage expansion.

D3 Engagement and Psychosocial Treatment of Youth with Opioid Use Disorders

Regency VII

Susan E. Caverly, PhD, Therapeutic Health Services, Seattle, WA

Among young opioid users, the impact of substances is magnified by life skill deficits, normal pressure for independence (expressed as oppositionality), adolescent omnipotence, and frequently coupled with psychiatric illness. This presentation describes an integrated psychosocial treatment approach based on the ENCOMPASS model. Standardized assessment and repeated measure outcomes are reported, demonstrating implication for structured motivational enhancement therapy, cognitive behavioral therapy, and contingency management, plus psychopharmacologic intervention to support engagement and therapy adherence. The importance of combining psychosocial therapy with pharmacologic interventions directed toward both psychiatric symptom management and medication assisted opioid treatment will be considered in context of treatment outcomes.

D4 Treat Anxiety and Reduce Benzodiazepine Use with Evidence-Based Intervention

Centennial III & IV

Lynn LeBlanc-Marrone, LMHC, Spectrum Health Systems, Inc., Worcester, MA
Lisa Blanchard, LMHC, Spectrum Health Systems, Inc., Worcester, MA

Anxiety disorders are prevalent in individuals with substance use disorders. While benzodiazepines are a commonly used and effective pharmacological treatment for anxiety, these medications may exacerbate addiction and increase clinical risk of overdose. The workshop will present a promising clinical intervention which provides patients non-pharmacological tools to manage anxiety through a cognitive behavioral therapy group curriculum. Data collected on group effectiveness, toxicology results, and patient surveys will be shared.

D5 Methadone Safety Guidelines for Treating Opioid Dependence & Chronic Pain

Centennial I

David Fiellin, MD, Yale University, New Haven, CT
Melissa Weimer, DO, CODA Opioid Treatment Program, Portland, OR
Dennis McCarty, PhD, Oregon Health & Science University, Portland, OR

The American Pain Society in collaboration with the College on Problems of Drug Dependence and the Heart Rhythm Society developed clinical practice guidelines to enhance safety when treating chronic pain and/or opioid dependence with methadone. Recommendations address a) the need for patient education, b) use of electrocardiography to identify patients at risk for cardiac arrhythmia, c) use of alternative medications, d) careful initiation and titration of methadone, and e) ongoing monitoring and follow-up. This session
Conference Sessions

**Tuesday, March 31, 2015**

will review the guidelines, the evidence base for the guidelines, and strategies for implementation of the guidelines in Opioid Treatment Programs.

**3:15 p.m.–4:45 p.m.**
Regency VII

**INTERNATIONAL PRESENTATIONS:**

**Outcome Measures in Heroin Addicted Patients Treated with Agonist Opioid Medication**

**Increasing Importance of Measuring Outcomes in Opioid Dependence Care**

Icro Maremmani, MD, Santa Chiara University Hospital, University of Pisa, Pisa, Italy

Heroin addiction represents a major public health issue. Specific actions have been introduced to improve services and promote recovery. Currently used outcome measures, such as access and retention in treatment, provide a limited picture of results. The most likely outcome for success is a combination of all the tools currently employed, but it will be essential to have the outcome measures in place to guide the decisions and ensure access to the right mix of appropriate services and interventions. Review of evidence shows that there is no holistic tool for measuring outcomes in opioid dependence care. Existing tools in opioid dependence care provide measures of progress at the patient level—a tool that allows comparison of outcomes above the patient level is needed.

**Reduction of Specific Psychopathology as Outcome Measure in Heroin Addicted Patients Treated with Agonist Opioid Medications**

Pier Paolo Pani, MD, Social Health Division, Health District 8 (ASL 8), Cagliari, Italy

Current “official” nosology (e.g. DSM 5) is largely limited to physical manifestations of addiction that can be objectively observed. However, addicted subjects display additional psychiatric symptoms that affect their well-being and social functioning and, in accordance with DSM nosological approach, are typically relegated to the domain of psychiatric “comorbidity.” Mood, anxiety, and impulse-control dysregulation are relevant in both the origins and clinical manifestations of addiction. Using the Self-Report Symptom Inventory (SCL-90), we studied the psychopathological dimensions of patients with heroin addiction at the beginning of treatment and their relationship with clinical conditions. We looked also at the impact of psychopathology on the outcome of treatment. We found that heroin-dependent patients may benefit from opioid agonist treatment not only because it targets their addictive problem, but also because it is effective against the associated mental problems.

**Reduction of Specific Addictive Behaviors and Improvement of Quality of Life as Outcome Measures in Heroin Addicted Patients Treated with Agonist Opioid Medications**

Angelo Giovanni Icro Maremmani, MD, School of Psychiatry, University of Pisa, Italy

The main goals of opioid treatment in heroin addiction are to eliminate or reduce the use of heroin and other substances of abuse, to reduce patients’ addictive behaviors, and to improve their quality of life. In this presentation we propose special quality of life and addictive behavior questionnaires. We present studies demonstrating one-year statistically significant improvements in quality of life, evaluated with this new questionnaire, for methadone or buprenorphine treated patients suggesting the long-term efficacy of methadone treatment and buprenorphine treatment on symptoms of opioid addiction and quality of life. In particular, patients treated with buprenorphine show a better improvement of quality of life especially regarding improvements in jobs, leisure activities, income, and self-acceptance when we considered markedly ill patients with severe impairment in their quality of life parameters.

**PRE-BANQUET COCKTAIL RECEPTION**

**Tuesday, March 31**

*Supported through a grant from CRC Health Group*
Awards Program

Tuesday, March 31, 2015

7:00 p.m.–9:30 p.m.
Centennial III & IV

Please join us for the centerpiece of our Conference, a moving tribute to those individuals who have been nominated and selected by their peers for extraordinary service in the opioid treatment community. These successful Award recipients have devoted themselves to improving the lives of patients in our treatment system. Dr. Vincent Dole and Dr. Marie Nyswander were the first recipients of this Award in 1983. The Association has been responsible for bestowing this honor since the first Regional Conference of 1984 in New York.

The Nyswander/Dole “Marie” Awards will be presented by Herman Joseph, PhD, National Drug Research Institute, New York, NY.

The 2015 American Association for the Treatment of Opioid Dependence Conference recognizes outstanding contributions to opioid treatment by honoring the following individuals with the Nyswander/Dole Award.

Henry Bartlett, MS, New York

Henry Bartlett has been in the field for more than 37 years, starting in 1977 in state government, transitioning in 2001 to representing the Opioid Treatment Program (OTP) community in New York as Executive Director of Committee of Methadone Program Administrators (COMPA), and in 2014 becoming the Associate Director for New York State Government Affairs with Alkermes. While still in state government, Henry initiated the restructuring of the Medicaid rates for OTPs which included automatic annual inflation trending, bringing millions of additional dollars annually to the treatment of opioid addiction. Continuing his advocacy while at COMPA, he obtained Medicaid rate equity for freestanding programs and favorable overall Medicaid rates for all OTPs. Henry's advocacy (both in state government and while at COMPA) has had the effect of adding more than two hundred million Medicaid dollars to the OTP treatment system in New York in the last 25 years. Henry has successfully prevented multiple program closures due to fiscal problems and difficulties in relocation. He has also been a driving force in the expansion of OTP services in upstate New York. At both the legislative and executive levels of state and local government, Henry has been a consistent advocate for all patients in New York to have access to evidence-based addiction treatment.

Donna Boone, MD, Illinois

Dr. Donna Boone has served as Medical Director at Wellspring Resources in Alton, Illinois, for nearly 26 years and is a compassionate physician and strong patient advocate. Dr. Boone was named Physician of the Year in 2012 by the Illinois Association for Medication Assisted Addiction Treatment for her dedication to delivering high quality treatment to each patient regardless of ability to pay. She has dedicated herself to the recovery of each individual in the program and proven to be a tremendous resource to the staff as well as the community. Her commitment extends to training staff in all areas of the organization. Dr. Boone has also educated primary care physicians on pregnancy and methadone, as well as serving as an advocate for her patients. She holds a deep respect for her patients and their right to self-determination. As a physician, she has raised the bar for patient care in the state of Illinois. Dr. Boone has made meaningful and consistent contributions that have had significant impact on opioid treatment in Illinois.

JoAn Brown, LAC, Louisiana

JoAn Brown is the owner, CEO, and Administrative Director of Choices of Louisiana, Inc., a multi-site Opioid Treatment Program (OTP). Ms. Brown is also a founding member of Louisiana’s Association for the Treatment of Opioid Dependence (LATOD) where she has served as President since 2000. With nearly two decades of dedication in advocating for the rights of patients enrolled in medication assisted treatment (MAT) programs, Ms. Brown utilizes the legal and legislative systems to increase patient access to OTP services and programs. Her involvement and strong belief in the benefits and credibility of methadone treatment prompted her to initiate a campaign to reduce OTP-related stigma and abolish prejudicial practices toward methadone patients by educating addiction treatment specialists and other professionals who provide MAT services. Ms. Brown has served as a board member of the Louisiana Addictive Disorder Regulatory Authority, being nominated by the Louisiana Association of Substance Abuse Counselors & Trainers, Inc. (LASACT) and appointed by the Governor for multiple terms. Among numerous awards and recognitions, Ms. Brown’s organization, Choices of Louisiana, received the Addiction Treatment Services Provider of the Year award from LASACT in 2010.

Richard Froncillo, LCDS, Pennsylvania

Richard “Ricky” Froncillo began his career in the substance abuse/addiction treatment field as an entry-level counselor in 1976. Since entering the field, he has been actively involved in associations that advocate for persons in recovery in multiple states. In 1999, he became active in the Pennsylvania Association for the Treatment of Opioid Dependence (PATOD) and in 2006 he was elected President of the organization, an office that he currently holds. PATOD represents the majority of medication assisted treatment programs in Pennsylvania and as the Chair of this group, Ricky was appointed to the Joint State Government Commission of the Distribution of Methadone and invited to participate on the buprenorphine access workgroup and the Value Behavioral Health workgroup that developed the Recovery Oriented Systems of Care for Opioid Treatment Programs. Pennsylvania legislators have proposed numerous bills directed towards Opioid Treatment Programs and patients treated in these facilities and Ricky has worked tirelessly to help educate these legislators. Since 1996, Ricky has worked with Discovery House, a national network of medication assisted treatment programs, in one of his roles as Board Member, in addition to his work with PATOD. Ricky currently serves as the Pennsylvania Director at Choices of Pennsylvania, Inc.
Awards Program

Tuesday, March 31, 2015

Sara Hartman, MSW, Massachusetts

Sara Hartman served 16 years as the Vice President of Mental Health for the Association for Behavioral Health care in Massachusetts. During her 16-year tenure, Sara worked on federal and state regulatory and monitoring, accreditation, healthcare reform, managed care policies, rate setting, access to care, and quality improvement initiatives. She helped establish the Opioid Treatment Providers Committee in 1999. Sara provided guidance to the providers, wrote state and federal testimony and regulatory feedback, represented and provided interface on behalf of the Opioid Treatment Providers with the Massachusetts Department of Public Health Bureau of Substance Abuse Services, Massachusetts Office of Medicaid, and managed care organizations. She was a major policy advocate during the 2002 and 2003 Massachusetts budget cycle in the successful fight to preserve Medicaid coverage for 10,000 individuals receiving services in OTPs. Sara has demonstrated unwavering dedication, compassionate leadership, commitment, and advocacy for methadone treatment. She has been a compassionate leader and has provided sincere advocacy for methadone treatment and is described by her colleagues as self-directed, organized, resourceful, trustworthy, and a conscientious professional.

Jason Kletter, PhD, California

Dr. Jason Kletter is the President of Bay Area Addiction Research and Treatment, which operates 22 Opioid Treatment Programs (OTPs) in five states. Dr. Kletter also serves as the President of the California Opioid Maintenance Providers (COMP) and as a Board Member of AATOD. Dr. Kletter has demonstrated excellence in many different aspects of the field as evidenced by support from colleagues, staff, patients, regulatory officials, and legislators. He is recognized in California for his determined patient advocacy and vocal support of increased access to high quality care with evidence-based practices. Those who know Dr. Kletter are familiar with his collaborative leadership and communication styles. Dr. Kletter is also known as an excellent resource given his exceptional knowledge base. This was highly evident in his work leading COMP providers through a political campaign to defeat the Governor’s budget proposal that would eliminate Medicaid funding for OTPs in California. Dr. Kletter developed and maintains a statewide conference on opioid treatment in California tailored specifically for OTP staff that includes many respected researchers and clinicians. He serves on the advisory board for the National Alliance for Medication Assisted Treatment (NAMA) Recovery and educates state policy makers on medication assisted treatment. Dr. Kletter has served as advisor to the California Department of Health Care Services, has participated in federal work groups with the Center for Substance Abuse Treatment initiatives as well as advising state legislators helping to craft sound policy into legislation.

Yngvild Olsen, MD, Maryland

Dr. Yngvild Olsen is the Medical Director for the Institutes for Behavior Resources in Baltimore and previously served as the Vice President of Clinical Affairs for the Baltimore City Substance Abuse Systems, as the Deputy Health Officer for the Harford County Health Department, and as the Medical Director for the Johns Hopkins Hospital’s outpatient substance use disorder treatment services. She is a graduate of Harvard Medical School, completed her residency training in internal medicine at Boston University’s Boston Medical Center, and received a Masters in Public Health from the Johns Hopkins Bloomberg School of Public Health. Throughout her career, Dr. Olsen has written and lectured extensively on addiction, opioid use disorder, and co-morbid medical issues. Dr. Olsen was recently published in the Journal of the American Medical Association on confronting the stigma of opioid use disorder and its treatment. She is a true patient advocate who works in her treatment center and in the community to help reduce the stigma of those affected by opioid addiction.

Lorenzo Somaini, MD, Italy

Dr. Lorenzo Somaini directs a hospital service unit specializing in addictions treatment following the methods and protocols of Drs. Dole and Nyswander. While primarily a practicing clinician, his mission also includes developing and delivering education and training for physicians and nurses on opioid agonist treatment. He conducts ongoing extensive research in such areas as the genetic factors influencing individual response to methadone and buprenorphine, the role of adverse childhood experiences in the development of addiction, and the immunologic effect of treatment. Dr. Somaini is a recognized expert on opioid agonist treatment and collaborates extensively with the Department for Antidrug Policies – Ministry for International Cooperation and Integration, Italy, the UN Office of Drug Prevention and Health, the Italian Society of Addiction Medicine, EUROPAD, the World Federation for the Treatment of Opioid Dependence, as well as Italian and international universities. He is also recognized for his contribution to the development of Ukraine’s national strategy on opioid dependence.

Rubie Walker, MA, Arizona

Rubie Walker, Program Director of Southwest Behavior Health Services, has been a member of the Arizona Coalition since 2003 and has served as Co-Chair for the past six years. Since her start with the Coalition, she has been enthusiastic, engaged, dedicated, and hardworking. She diligently educates community members about the benefits of medication assisted treatment (MAT). Rubie is well known and respected throughout the behavioral health treatment community for her work with victims and perpetrators of domestic violence, juvenile court incarcerated and adjudicated youth, Head Start, and other agencies.
She has tirelessly fought for better MAT, both in her facility and in all of Arizona. The natural enthusiasm with which she approaches every challenge has resulted in challenging others to become better educated about treatment, to be better advocates for treatment, and to be better equipped to meet the challenges. Arizona is deeply grateful to Rubie, who has never quit battling the systems that try to deny people the opportunity for MAT and for a better future for themselves and their families. The treatment community in Arizona is a better place because of Rubie.

FRIEND OF THE FIELD AWARD
Presented by Mark W. Parrino, MPA, AATOD President

The prestigious Friend of the Field Award was established by AATOD’s Board of Directors. This award recognizes extraordinary contributions to the field of opioid treatment by an individual whose work, although not directly related to opioid treatment, has had a significant impact on our field. The 2015 Friend of the Field Award has been awarded to:

The Honorable Peter Shumlin, Governor of Vermont

Governor Peter Shumlin’s career in public service began more than 30 years ago when at the age of 24 he was elected to serve on Putney, Vermont’s select board.

In 1990, he was appointed to fill an empty seat in the Vermont House of Representatives where he served for three years. He then served eight terms in the Vermont Senate and was elected by his colleagues to lead the Senate as President pro temore during that time. Elected Governor in 2010, he recognized the reality of the rising opioid related deaths in Vermont. In June 2013, Gov. Shumlin signed into law two bills aimed at reducing the toll of drug overdose deaths in the state. In 2014, Governor Shumlin decided to take a bold approach to this problem and devoted his entire “State of the State Address” to this public health crisis. In this call-to-arms speech, the Governor outlined an ambitious program to address opioid addiction. Since then, he has implemented plans increasing access and funding to addiction treatment programs and has had a significant impact on the surrounding region. Vermont is now said to lead the country in addressing opioid overdose through broad scale and comprehensive overdose prevention legislation. The Governor is currently working with other governors in New England to be certain that he is doing all he can to increase access to quality addiction treatment services.

Governor Shumlin is being recognized for his holistic approach in confronting this public health crisis and the passion and energy he brings to this issue.

RICHARD LANE/ROBERT HOLDEN PATIENT ADVOCACY AWARD
Presented by Joycelyn Woods, MA & Walter Ginter, CMA

Richard Lane was a long-term heroin user who, upon release from prison in 1967, was instrumental in establishing one of the Nation’s first methadone treatment programs. In 1974, he became the Executive Director of Man Alive and later served as Vice President of the American Methadone Treatment Association and as Vice Chairman of the Governor’s Council on Alcohol and Drug Abuse in Maryland. Mr. Lane was a passionate advocate for methadone treatment and, by disclosing his own treatment experiences, provided inspiration to patients and colleagues alike. Robert Holden was also a recovering heroin user, who later became the Director of PIDARC, an outpatient methadone treatment program in the District of Columbia. He later served as the Vice President of AATOD, succeeding Richard Lane’s term of office. This award was established in 1995 and recognizes extraordinary achievements in patient advocacy.

Claude Hopkins, CADC

Claude Hopkins serves as a National Grievance Coordinator for National Alliance for Medication Assisted Recovery (NAMA-R), Substance Abuse Counselor and Patient Advocate for JSAS HealthCare, serves on NAMA-R Board of Directors as a State Chapter Director, and is a member of “Stop Stigma Now.” Claude Hopkins applies over 40 years of his own personal recovery on methadone to help others still struggling with their addiction. He has established positive working relationships at the state and national level enhancing his ability to be an effective advocate and changing negative attitudes regarding the efficacy of medication assisted treatment (MAT). Claude previously served as a Patient Representative in New Jersey’s Citizen’s Advisory Committee, has served as a NJ Representative to “Faces and Voices of Recovery,” and is currently a Consultant to the NJ State Opioid Treatment Authority. Claude is described as an authentic, willing, and devoted Advocate. He has had a positive effect on NJ’s policies and practices as they relate to MAT. He is intelligent and balanced in his approach to challenges, which lends itself to positive outcomes for patients in the state of New Jersey.
E3 Meeting the Need: Enhancing the Utilization of PAs-NPs in OTPs

**Centennial II**

Jim Anderson, PA-C, Evergreen Treatment Services, Seattle, WA  
Ron Jackson, LICSW, University of Washington, Seattle, WA  
Paul Grekin, MD, Evergreen Treatment Services, Seattle, WA  

With the Affordable Care Act (ACA) now firmly in place, access to Opioid Treatment Program (OTP) care has skyrocketed. Programs across the country face challenges in finding providers capable of providing high-quality care for the growing patient population. This workshop will address this challenge and describe the benefits of enhanced utilization of Physician Assistants (PAs) and Nurse Practitioners (NPs), offering a historical framework of the deployment of PAs and NPs in OTPs, examining available data about safety, scope of practice, and quality of care issues related to PA-NP practice, and describing strategies to meet the needs of a growing patient population in the context of ACA implementation.

E4 Best Practice Guidelines for Recovery-Oriented Methadone Maintenance

**Centennial I**

James M. Schuster, MD, Community Care Behavioral Health Organization, Pittsburgh, PA  
Margaret E. Hanna, MEd, Community Care Behavioral Health Organization, Pittsburgh, PA  

This workshop describes Supporting Recovery from Opioid Addiction: Community Care Best Practice Guidelines for Recovery-Oriented Methadone Maintenance—which blend the latest national consensus guidelines and the work of William L. White, MA and Lisa Mejor-Torres, JD (Recovery-Oriented Methadone Maintenance, 2010). Community Care, a provider owned behavioral health not-for-profit managed care company, partnered with counties, providers, and persons in recovery in this effort. Presenters will review the content, especially the role of medication assisted treatment in recovery and quality of care concerns, and also discuss challenges in practical applications of these guidelines. Development methodology and lessons learned will also be shared.

E5 Treating Pain and SUD to Prevent, Treat, and Educate on HCV and HIV

**Regency VII**

Andrew Talal, MD, University of Buffalo, Buffalo, NY  
Michael Saenger, MD, Atlanta Veterans Administration Medical Center, Atlanta, GA  

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections are a common occurrence in opioid dependent intravenous drug users. However, recent advances have now produced medications that significantly improve treatment efficacy and outcomes for HCV patients. Recent literature notes patients are very open.

---

**WORKSHOP SESSIONS**

8:00 a.m.–9:30 a.m.

**E1 Smoking Cessation Made Easy, or How to Save $2,250 or More per Year!**

**Regency VI**

Abigail Kay, MD, Thomas Jefferson University, Philadelphia, PA  

If quitting smoking were only a matter of self-control, most would be successful. As the medical consequences are so severe, it is key that all treatment team members have an understanding of different options available to help people quit. This workshop focuses on medication assisted treatments for smoking cessation. It is designed to be accessible to the entire treatment team, from the peer counselor to the physician. Over-the-counter, as well as prescription medication options, will be covered. Additionally, smoking cessation for those with co-occurring psychiatric diagnoses and a review of physiological reasons that make quitting more challenging will be discussed.

*Basic Track*

**E2 Legal Cannabis Use: Emerging Treatment Challenges in Methadone Treatment**

**Centennial III & IV**

Alan Lee Nolan, LCSW, Connecticut Counseling Centers, Inc., Norwalk, CT  

Medical and legal cannabis use is becoming an increasing focus within Methadone Maintenance Treatment Programs (MMTP). This workshop will focus on the unique challenges involved with addressing the evolving role of medical marijuana for patients enrolled in a MMTP. The presenter will examine the numerous questions relating to marijuana’s potent psychoactive properties and associated risk management concerns, the inconclusive empirical data regarding adverse health consequences and how these questions are creating serious challenges for providers and ultimately impacting treatment models, policy decisions, and consumer perspectives. An analysis of the potential service implications of marijuana use among MMTP patients will be explored.
to receiving treatment for HCV in an Opioid Treatment Program (OTP) environment. Similarly, OTPs already have existing regulatory requirements to provide interventions to HIV-infected patients. The literature suggests that engagement in medication assisted treatment reduces risky behavior and increases positive outcomes for opioid dependent HIV-infected patients. Given the existing structure for managing complex patients, OTPs are uniquely positioned to address HCV and HIV with opioid dependent patients.

9:45 a.m.–11:15 a.m.

F1 Buprenorphine Updates

Centennial III & IV

Melinda Campopiano, MD, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
Alexandra Nielsen, MS, Portland State University, Portland, OR

This session provides an update on federal policy on the use of buprenorphine for opioid dependence. SAMHSA promulgated new regulations increasing flexibility for patients of Opioid Treatment Programs treated with buprenorphine. Moreover, SAMHSA held a Buprenorphine Summit in 2014 to develop recommendations on how to advance the field. In addition, a SAMHSA study will be presented using a computational policy model for understanding the interactions between buprenorphine treatment capacity, costs, and public health and safety. The model is used to answer questions about the impact of lifting the patient cap and including advanced practice providers as prescribers.

*Basic Track

F2 Preventing Premature Discharges & Alternatives to Administrative Discharges

Centennial II

Robert L. DuPont, MD, Institute for Behavior and Health, Inc., Rockville, MD
Howard Hoffman, MD, Foundation for Contemporary Mental Health, Washington, DC

A significant challenge in treating opioid dependence is noncompliance to treatment, including the continued use of non-prescribed drugs and low attendance. This workshop discusses strategies to prevent premature discharge, including interventions in response to non-adherence by the methadone treatment program. Partners in Drug Abuse Rehabilitation and Counseling (PIDARC) in Washington, DC utilizes a series of protocols and interventions to retain patients in treatment before imposing administrative discharge. Continued use of non-prescribed drugs is a risk factor for premature termination of methadone maintenance treatment. This workshop presents lessons learned from PIDARC including research findings and implications for other treatment programs.

F3 VT’s Hub and Spoke Model for Opioid Addiction

Regency VII

John R. Brooklyn, MD, University of Vermont College of Medicine, Clinical Assistant Professor of Family Medicine and Psychiatry, Burlington, VT
Anthony Folland, BA, Vermont State Opiate Treatment Authority, Alcohol and Drug Abuse Programs, VT Dept of Health, Burlington, VT

Hub and Spoke is a comprehensive treatment system for patients receiving medication assisted treatment for opioid dependence. The Vermont Hub and Spoke model for treating opioid dependency will be discussed from its inception to the current time. We will discuss the underlying basis for creating this system of care based on challenges in adequately reaching all opioid addicts and coordinating the appropriate level of care in this rural state. Funding and regulatory support under Vermont’s Chronic Care Initiative as part of the Blueprint for Health will be discussed.

F4 Selecting, Implementing and Maximizing the Benefits of an Electronic Health Record (EHR) at Your Opioid Treatment Program

Centennial I

Susan Hayashi, PhD, JBS International, Inc., Bethesda, MD
Gregory Warren, MA, Trident Group, LLC, Baltimore, MD
Sharon Dow, MS, DB Consulting Group, Inc., Silver Spring, MD

Substance Abuse and Mental Health Services Administration (SAMHSA) has indicated that Opioid Treatment Program (OTP) adoption of EHRs is a major gap in achieving health information technology (HIT) interoperability. To help OTPs more actively participate in HIT and make the transition to EHRs, this panel will build on previous efforts by AATOD and SAMHSA to discuss key lessons learned from OTP EHR implementation case studies, best practices for sustaining a successful EHR system and maximizing its use, and available resources about EHRs for OTPs, including a free online EHR portal community for OTPs.

F5 SAMHSA’s Tobacco Cessation for Opioid Treatment Programs

Regency VI

Deborah Petska, MA, Danya International, Inc., Silver Spring, MD
Phillip Wilbur, MA, Danya International, Inc., Silver Spring, MD

This workshop will provide participants with the knowledge and tools that will enable them to determine the appropriateness of the tobacco cessation program for their treatment facilities and assess the readiness of their tobacco-addicted patients. The presentation will focus briefly on the importance of a tobacco cessation program that specifically addresses the OTP patient population. An overview of the tobacco cessation program and its fundamental principles will also be provided. There will be a strong emphasis on how the stages of change and a patient-driven approach are effective methods to encourage abstinence from tobacco in OTP patients.
Conference Sessions

Wednesday, April 1, 2015

CLOSING PLENARY SESSION

11:30 a.m.–12:45 p.m.

The Federal Response to the Opioid Dependence Crisis

Centennial III & IV

MODERATOR:
Mark W. Parrino, MPA, President, American Association for the Treatment of Opioid Dependence, Inc. (AATOD), New York, NY

SPEAKERS:
Michael P. Botticelli, MEd, Director, Office of National Drug Control Policy (ONDCP), Washington, DC
Pamela S. Hyde, JD, Administrator, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD

The White House Office of National Drug Control Policy (ONDCP) and the Substance Abuse and Mental Health Services Administration (SAMHSA) are the two leading federal agencies involved in developing and implementing drug addiction policies in the United States. We are fortunate to have their leaders close our conference, advising attendees on how their agencies are working to effectively coordinate policy into the future. Mr. Michael Botticelli will provide an understanding of how ONDCP is responding to the public health crisis of opioid addiction in the United States, focusing on the National Drug Control Strategy and ONDCP specific initiatives to confront this public health challenge. Administrator Pamela Hyde will focus on SAMHSA’s past, current, and future efforts to address the need for increased treatment in order to provide access to care for people who are clearly in crisis. It is an important closing to our conference as we prepare to deal with the challenges that lie ahead in an era of increasing opioid addiction.

Passing the Baton:
Announcement of the 2016 Conference Site

Jonathan P. Connell, MA; Mark W. Parrino, MPA; and Vickie L. Walters, LCSW-C

2016 AATOD Conference
October 29–November 2, 2016
Baltimore Marriott Waterfront
Baltimore, MD

CLINIC TOURS

1:00 p.m.–3:30 p.m.
(subject to change)

Visit the Hospitality Table on-site for more information and to sign up for the tours.

Alliance Recovery Centers—Decatur & Conyers

Alliance Recovery Centers (ARC) opened as an Opioid Treatment Program in 1996. ARC is a privately owned provider operating in Decatur, Conyers, and Athens, Georgia. ARC is a current contract provider for The Department of Behavioral Health and Developmental Disabilities and the Veterans Administration. ARC prides itself on providing clean, safe, and comfortable facilities and a professional, graduate level counseling staff.

Southside Medical Center

Southside Behavioral Lifestyle Enrichment Center (SBLEC) is one of Southside Medical Center’s specialty areas, providing services to men and women aged 18 and older with mental health and/or substance abuse issues. SBLEC currently has two main programs of service, the Opioid Treatment Program (OTP) and the Adult Mental Health program. Clients of SBLEC also have access to all of Southside Medical Center’s areas of health care to ensure that the whole person is treated and cared for.
A SPECIAL NOTE FOR THE DISABLED

The American Association for the Treatment of Opioid Dependence, Inc. has taken steps required to ensure that no individual with a disability is excluded, denied services, segregated or otherwise treated differently than other individuals because of the absence of auxiliary aids and services, as outlined in the Americans with Disabilities Act.

CONTINUING MEDICAL EDUCATION (CME)/CONTINUING EDUCATION HOURS (CEHS)

The AATOD 2015 Conference will award Continuing Medical Education (CME) and Continuing Education Hours (CEHs).

To apply for CMEs / CEHs, conference attendees must pay the associated fee, either in advance or at the on-site conference registration desk. Attendance at conference events will be verified electronically. Each attendee seeking CMEs / CEHs will have an electronic code attached to his/her conference badge. At the end of EACH approved session, attendees must have their badges “scanned” by room monitors in order to record CME / CEH.

These monitors will have electronic equipment that will automatically record each individual’s attendance in a database. The database will track and tabulate each attendee’s CMEs / CEHs. After the conference, certificates documenting attendance and the number of CMEs / CEHs earned will be electronically generated and emailed to all eligible attendees.

Attendees participating in ALL six Basic Track workshops will receive an additional certificate documenting their participation in this special training series. Questions about CMEs / CEHs can be answered by staff at the Conference CME / CEH Desk located in the registration area.

2015 Continuing Medical Education
AMA Credit Designation Statement:
The American Society of Addiction Medicine designates this live activity for a maximum of 28 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint provision of The American Society of Addiction Medicine and The American Association for the Treatment of Opioid Dependence, Inc.

The American Society of Addiction Medicine is accredited by the ACCME to provide continuing medical education for physicians.

2015 Continuing Education Hours

NAADAC—AATOD is an approved provider through NAADAC, the Association for Addiction Professionals, Provider #00218. This program meets the criteria for up to 36.75 hours of continuing education.

NBCC—This program has been approved by the National Board for Certified Counselors (NBCC) for up to 36.75 NBCC Credit. AATOD is solely responsible for all aspects of the program. NBCC Approval No. SP-2480

ASWB—AATOD, provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB), www.aswb.org, through the Approved Continuing Education (ACE) program. The American Association for the Treatment of Opioid Dependence (AATOD) maintains responsibility for the program. ASWB Approval Period: 6/12/2013 – 6/12/2016. Social workers should contact their regulatory board to determine course approval. Social workers participating in this course will receive up to 36.75 (clinical or social work ethics) continuing education clock hours. Please visit the AATOD website (www.aatod.org) for more information on specific learning outcomes and objectives, the target audience and the number of credit hours awarded for all conference sessions from the ASWB.

GNA—An application has been submitted to the Georgia Nurses Association Continuing Education Review Committee for approval of 36.75 contact hours. Please call Alexandra Springer at the American Association for the Treatment of Opioid Dependence for more information.

GAMFT—The Georgia Association for Marriage and Family Therapy has approved the 2015 AATOD Conference for up to 36.75 Core Education continuing education contact hours. The Approval ID is #019-2015.

A complete listing of credits approved for offered sessions is available in the registration materials or at the CE Desk in the registration area. For more information regarding continuing education credits/hours, please email aatod@talley.com or call Alexandra Springer at 856-423-3091.
On behalf of the AATOD Hospitality Committee, I would personally like to welcome you to my hometown of Atlanta, Georgia. We'll be convening at the Hyatt Regency Atlanta, conveniently located in downtown, within walking distance to many attractions, dining options and public transportation. For those flying in and out of Atlanta’s Hartsfield-Jackson International airport, the MARTA offers a quick and economical option to and from the Hyatt Regency without going outside. Easy!

Atlanta features a truly extraordinary dining scene and we hope that you’ll take some time at the end of your day to explore some of our culinary options. Atlanta is home to Kevin Gillespie’s Gunshow, one of America’s most cutting-edge restaurants and a *Bon Appetit* best new restaurant short lister. If seafood suits your palate, Ford Fry’s The Optimist is the best in the city. Atlanta is the birthplace of new southern cuisine. If you are interested in trying a southern original, some of the best include Miller Union, JCT Kitchen, Empire State South and Watershed. Are you in the mood for some traditional southern comfort food? May Mac’s Tea Room is only a couple of train stops away. No matter what you have a taste for, we can meet and exceed your expectations. Just stop by the hospitality table and we will point you in the right direction!

If you are looking to fill your downtime during the conference, there are many attractions within walking distance of the Hyatt Regency. Centennial Olympic Park, the Sky View Ferris Wheel, the World of Coca-Cola, the Georgia Aquarium, the College Football Hall of Fame, and the National Center for Civil and Human Rights are all just a short walk away. Please use our conveniently located public transit system, MARTA, to explore more of our city. Within a few short train stops you can reach the Fabulous Fox Theatre, Piedmont Park and the adjacent Atlanta Botanical Garden, The High Museum of Art, the midtown shopping district, the Martin Luther King Jr. historic site and Oakland Cemetery. If you are interested in Atlanta’s contributions to science and medicine, please join us for a tour of the nearby Centers for Disease Control and Prevention.

The hospitality committee is very excited and pleased to host you in Atlanta. We have a wonderful program in store for you and we will work our hardest to make sure your stay in Atlanta is a pleasurable one. Please do not hesitate to stop by the hospitality table with any questions you might have about our city. We won’t steer you wrong!

Sincerely,
Brook Etherington, MA
Hospitality Chair
The American Association for the Treatment of Opioid Dependence, Inc. (AATOD) was founded in 1984 to enhance the quality of patient care in treatment programs by promoting the growth and development of comprehensive opioid treatment services throughout the United States. AATOD works with federal agencies, state substance abuse authorities and agencies within the criminal justice system concerning opioid treatment policy in addition to coordinating activities with advocacy groups and treatment providers in all regions of the country. AATOD continues to work on behalf of all its members by expanding access to quality addiction treatment services.

Accumedic
Booth # 121
11 Grace Avenue, Suite 401
Great Neck, NY 11021
Phone: (800) 765-9300
Fax: (516) 466-6880
Email: john@accumedic.com
Web: www.accumedic.com

Accumedic continues to define the standard of excellence in Behavioral Healthcare IT with software that effectively manages your programs in a single solution. Intuitive and easy-to-use, AccuMed™ EHR integrates every aspect of your clinical documentation and revenue cycles. AccuMed is the ONC certified intelligent solution designed to simplify your workflow.

ACM Medical Laboratory
Booth # 304
160 Elmgrove Park
Rochester, NY 14624
Phone: (800) 525-5227
Email: tdepalma@acmlab.com
Web: www.acmlab.com

ACM Medical Laboratory offers an extensive range of testing solutions for addiction treatment and monitoring of controlled substances. Our goal is to provide behavioral health facilities, methadone and suboxone clinics, and drug and alcohol treatment centers with the most up-to-date substance abuse testing options and highest quality results to aid them in the diagnosis and treatment of their patients.

Addiction Technology Transfer Center Network
Booth # 201
1513 University Avenue
Madison, WI 53706
Phone: (608) 265-6276
Fax: (608) 890-1438
Email: hmkahle@wisc.edu
Web: www.attcnetwork.org

The ATTC network, funded by SAMHSA, improves the quality of services to treat and support recovery from opioid and other addictions. The ATTC Network promotes the adoption and implementation of evidence-based clinical practices through such activities as awareness training, distance education, skill-building workshops, change management consulting, publications, and web resources.

Advix® - Electronic Health Record
Booth # 300
213 Court Street
Middletown, CT 06457
Phone: (855) 329-2290
Fax: (860) 638-5302
Email: ebass@advixehr.com
Web: www.advixehr.com

Advix is a complete web-based EHR developed by behavioral health professionals. Say NO to difficult and expensive systems: say YES to Advix, an affordable, comprehensive EHR and practice management system for ambulatory, residential and medication assisted behavioral health services (including methadone dispensing), supported by world-class customer service.

Aeon Clinical Laboratories
Booth # 317
2225 Centennial Drive
Gainesville, GA 30504
Phone: (678) 276-8412
Fax: (678) 890-1438
Web: www.aeonclinical.com

Aeon Clinical Laboratories is a clinical toxicology lab. Our 28,000-square-foot facility is CLIA approved and equipped with HPLC-tandem mass spectrometers. The combination of our state-of-the-art technology and 3-step report review process ensures precision and accuracy of all results. We also offer pharmacogenomics testing services. We want our clients to have all the tools to be able to Prescribe with Confidence®. What sets us apart from our competitors is our unparalleled customer service; we pride ourselves on being client focused.

Alkermes, Inc.
Booth # 111
852 Winter Street
Waltham, MA 02451
Phone: (781) 609-6000
Web: www.alkermes.com

Alkermes is a fully integrated biopharmaceutical company that applies its scientific expertise and technological know-how to develop innovative medicines designed to yield better therapeutic outcomes for patients with central nervous system (CNS) disorders, including addiction, schizophrenia and depression. For more information, please visit www.alkermes.com.

American Academy of Addiction Psychiatry
Browse Table #1
400 Massasoit Avenue, Suite 307
East Providence, RI 02914
Phone: (401) 524-3076
Fax: (401) 272-0922
Email: info@aaap.org
Web: www.aaap.org

The American Academy of Addiction Psychiatry (AAAP) is the best professional membership organization for learning and sharing about the art and science of Addiction Psychiatry research and clinical treatment.
American Screening
Booth # 202
1651 East 70th Street PMB 404
Shreveport, LA 71105
Phone: (318) 798-3306
Fax: (318) 798-3386
Email: sales@americanscreeningcorp.com
Web: www.americanscreeningcorp.com
American Screening Corporation, an ISO 13485 certified company, has called Shreveport, LA home since beginning operations in January 2004. Our drug testing products are designed for maximum accuracy with up to 99% accuracy rate, FDA 510K approval & CLIA Waived.

American Society of Addiction Medicine
Booth # 309
4601 North Park Avenue, Suite 101
Chevy Chase, MD 20815
Phone: (301) 656-3920
Fax: (301) 656-3815
Email: member@asam.org
Web: www.asam.org
ASAM is a professional society representing over 3,000 physicians and associated professionals dedicated to increasing access and improving the quality of addiction treatment; educating physicians, other medical professionals and the public; supporting research and prevention; and promoting the appropriate role of physicians in the care of patients with addiction.

Atlantic Diagnostic Laboratories, LLC
Booth # 208
3520 Progress Drive, Suite C
Bensalem, PA 19020
Phone: (267) 525-2470
Fax: (267) 525-2488
Email: info@adlab.net
Web: www.adlab.net
The Premier Behavioral Health Laboratory on the East Coast, providing specialized testing to our Methadone Maintenance Clients. Drug testing is performed on urine, oral and blood samples, with all positives confirmed by our industry leading, comprehensive LC/MS/MS testing, in our state-of-the-art 27,000+ square foot facility.

BHbusiness
Booth # 318
1400 K Street, Suite 400
Washington, DC 20005
Phone: (202) 684-7457
Fax: (202) 386-9391
Email: daisyw@thenationalcouncil.org
Web: www.bhbusiness.org
BHbusiness offers customized technical assistance and training to behavioral health executives to help you identify and implement change projects that expand service capacity, utilize new payer sources and thrive in the changing health care environment. All assistance is fully funded by SAMHSA.

BioDelivery Sciences International, Inc.
Booths #203 & 307
801 Corporate Center Drive, Suite 210
Raleigh, NC 27607
Phone: (919) 582-9050
Fax: (919) 582-9051
Email: mmichael@bdsi.com
Web: www.bdsi.com
BioDelivery Sciences is a specialty pharmaceutical company focusing on pain and addiction medicine. We utilize novel BioErodible Mucoc-Adhesive (BEMA) advanced delivery technology to provide new applications of proven therapies to address critical unmet medical needs. We look forward to working with you to enhance patient care.

C&C Containers
Booth # 226
2607 Ledo Road
Albany, GA 31707
Phone: (229) 888-2077
Fax: (888) 872-7921
Email: info@cccontainers.net
Web: www.cccontainers.com
“Great products, better pricing, best customer service, and home of the foil seal.”

Calloway Labs
Booth # 326
12 Gill Street
Woburn, MA 01821
Phone: (781) 783-2842
Fax: (888) 729-0826

CARF International
Booth # 209
6951 East Southpoint Road
Tucson, AZ 85756
Phone: (520) 325-1044
Fax: (520) 495-7128
Email: bharrison@carf.org
Web: www.carf.org
Founded in 1966, CARF is an international, nonprofit accreditor of human service providers and networks. A provider earns accreditation by demonstrating conformance to CARF’s internationally recognized standards in areas that span the continuum of life. More than 8.7 million persons of all ages are served annually in CARF-accredited programs. www.carf.org

Clinical Science Lab
Booth # 122
51 Francis Avenue
Mansfield, MA 02048
Phone: (800) 255-6106
Fax: (508) 339-3540
Email: donwbaker@aol.com
Web: www.clinicalsclab.com
Since 1974 we have served treatment, detox, prevention, and criminal justice facilities. We provide fast 24-hour turnaround time at very competitive rates. We provide a full menu of drug testing and blood testing that is all performed on-site daily. Our laboratory is licensed by C.L.I.A. and Accredited by CAP.

Council on Accreditation
Booth # 312
45 Broadway, 29th Floor
New York, NY 10006
Phone: (212) 797-3000
Fax: (212) 797-1428
Email: jseoane@coanet.org
Web: www.coanet.org
The Council on Accreditation (COA) is an independent, nonprofit, human service accrediting organization. COA accredits or in the process of accrediting more than 2,200 organizations and programs serving more than 7 million individuals and families internationally. We currently accredit over 45 different service areas that apply to over 125 types of programs.
March 28–April 1, 2015 | Atlanta, Georgia

**CRC Health Group**  
Booth # 319  
6185 Paseo Del Norte, Suite 150  
Carlsbad, CA  92011  
Phone: (865) 806-4372  
Fax: (270) 682-5637  
Web: www.crchealth.com

CRC Health Group is the largest, most comprehensive network of specialized behavioral healthcare services in the nation. CRC offers the largest array of personalized treatment options, allowing individuals, families and professionals to choose the most appropriate treatment setting for their behavioral, addiction, weight management and therapeutic education needs. CRC is committed to making its services widely and easily available, while maintaining a passion for delivering advanced treatment.

**CSS Inc.**  
Booth # 325  
20 E. Clementon Road, Suite 201-S  
Gibbsboro, NJ  08026  
Phone: (856) 544-7000  
Fax: (856) 627-5696  
Email: MChalenski@csscheck360.com  
Web: www.csscheck360.com

CSS partners with companies to achieve their goals by providing reliable data, valuable insight and efficient solutions. CSS offers background screening, laboratory testing, and workforce monitoring solutions that are customized to your unique needs and tailored to help you achieve your goals as an organization.

**Drugscan**  
Booth # 305  
200 Precision Road  
Horsham, Pennsylvania  19044  
Phone: (800)235-4890  
Fax: (692)627-5696  
Email: Phillip.rocco@drugscan.com  
Web: www.drugscan.com

Drugscan is Fast, Professional, Accurate & Responsive. One of only a few nationally CAP accredited and certified SAMHSA toxicology laboratories; DRUGSCAN is a leader in clinical and forensic toxicology, medication monitoring, and drug detection laboratory services. At DRUGSCAN, our mission is to keep everyone in the patient care continuum safe and compliant with all regulations; providing clients with advanced technology, accurate results, and superior customer service.

**Harwoods Miami Safe Co.**  
Booth # 211  
7350 SW 45 Street  
Miami, FL  33155  
Phone: (305) 389-0517  
Fax: (305) 266-5821  
Email: jackbagwell@miamisafe.net

Nationwide sales and service of high security safes and modular vaults for the Pharmaceutical Industry.

**Hazelden Publishing**  
Booth # 306  
15251 Pleasant Valley Road  
Center City, MN  55012  
Phone: (800) 328-9000  
Fax: (651) 213-4577  
Email: athill@hazeldenbettyford.org  
Web: www.hazeldenbettyford.org

Hazelden is best known for providing proven-effective addiction treatment, recovery, and prevention books, videos, and curricula to individual consumers, treatment programs, schools, hospitals, mental health agencies, and correctional facilities. As a leading expert on prevention, addiction, treatment, and recovery, Hazelden works to build awareness and understanding about effective prevention and treatment.

**Indivior**  
Reckitt Benckiser Pharmaceuticals Inc is a subsidiary of Indivior PLC  
Booth # 320  
10710 Midlothian Turnpike, Suite 430  
Richmond, VA  23235  
Phone: (804) 379-1090  
Web: Indivior.com

The Indivior Group is a global speciality pharmaceutical company providing educational resources and potential treatment options for opioid dependence. Please visit their exhibit to discuss their approved indication.

**Laboratory Corporation of America** (LabCorp)  
Booth #112  
69 First Avenue  
Raritan, NJ  08869  
Phone: (212) 698-0307  
Fax: (855) 800-8430  
Email: melzers@labcorp.com  
Web: www.labcorp.com

LabCorp makes available drug screening profiles that are designed to assist treatment professionals with monitoring patients’ drug use. In addition to detecting commonly abused prescription and illicit drugs, LabCorp’s Substance Abuse Recovery options test for medications commonly used to treat addiction, such as Suboxone® (buprenorphine) and methadone. We also offer ethyl glucuronide (EtG) and ethyl sulfate (EtS) to extend the detection time of alcohol use, and offer tests for contemporary abuse of substances such as synthetic cannabinoids. Tests for urine and oral fluid are available.

**Mallinckrodt Pharmaceuticals**  
Booth # 103  
675 McDonnell Boulevard  
Hazelwood, MO  63042  
Phone: (314) 654-2000  
Web: www.mallinckrodt.com

Mallinckrodt Pharmaceuticals is a global specialty pharmaceutical business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. We provide customers with a broad portfolio of specialty generics to treat pain, ADHD, opiate and alcohol addiction, depression and insomnia. For more information, visit www.mallinckrodt.com.

**MARS Project**  
Booth # 301  
804 East 138th Street  
Bronx, NY  10454  
Phone: (718) 742-7804  
Email: mardsdirector@yahoo.com  
Web: www.marsproject.org

MARS™ (Medication-Assisted Recovery Services) is The Peer Community of Recovery Support and Training. Beyond MARS™ provides training to replicate this model. There are currently 14 MARS™ sites across the US and 4 projects in development in Vietnam. We also provide Recovery Coach Training and lead NY’s Statewide Peer Recovery Network.

**MedComp Sciences**  
Booth # 310  
20203 McHost Road  
Zachary, LA  70791  
Phone: (225) 570-8487  
Fax: (225) 570-8487
Email: Brianna.scalici@medcompsciences.com
Web: www.medcompsciences.com
MedComp Sciences is parent company to subsidiaries including, MedComp GX – pharmacogenetic analysis, MedComp TOX – therapeutic medication monitoring, MedComp RX – general compounding and pharmacy offerings and MedComp Pain – providing nerve therapy devices to patients with acute and chronic pain.

MethodOne
Booth # 124
20436 Route 19, Suite 620, Box 180 Cranberry Township, PA 16066
Phone: (724) 371-1199
Fax: (724) 304-0166
Email: info@computalogic.com
Web: www.computalogic.com
MethodOne web-based Software includes everything you need to effectively and efficiently manage your behavioral health care center from anywhere anytime. MethodOne is flexible and configured to work with your processes and procedures. It is extremely affordable and comes with unparalleled customer support. Isn’t it time you reevaluated your software?

Millennium Health
Booth # 311
15330 Avenue of Science
San Diego, CA 92128
Phone: (877) 451-3534
Web: www.millenniumhealth.com
Millennium Health is a leading health solutions company that delivers accurate, timely, clinically actionable information to inform the right treatment decisions for each patient at the right time. Millennium offers a comprehensive suite of services to better tailor patient care. More information is available at www.millenniumhealth.com

NAADAC
Booth # 218
1001 N. Fairfax Street, Suite 201 Alexandria, VA 22314
Phone: (703) 741-7686
Fax: (703) 741-7698
Email: Naadac@naadac.org
Web: http://www.naadac.org
NAADAC, the Association for Addiction Professionals, represents the professional interests of more than 85,000 addiction counselors, educators, and other addiction-focused healthcare professionals in the United States and abroad. NAADAC’s members and 47 state affiliates work to create healthier individuals, families, and communities through prevention, intervention, quality treatment, and recovery support.

Naples Medical Devices, LLC
Booth # 314
Naples, Florida
Phone: (239) 250-7404
Email: info@naples-medical-devices.com
Web: www.naples-medical-devices.com
Naples Medical Devices introduces a new methadone dispenser called iMeasure. iMeasure dispenses by weight, which means more accuracy, no more costly pump calibrations and no air bubble issues. iMeasure is also capable of handling and emptying all methadone bottles on the market. Try iMeasure today at booth 314.

Netalytics
Booth # 303
102 Trade Street
Greer, SC 29651
Phone: (864) 416-0153
Fax: (864) 416-0157
Email: jsmith@netalytics.com
Web: www.Netalytics.com
Methasoft® is an industry leading product for the management and provision of care in the opioid treatment arena. Methasoft is a completely integrated system from patient check-in kiosk to billing. Methasoft is fully automated, flexible software that utilizes leading technologies including Microsoft.NET Framework and SQL Server.

Netsmart
Booth # 104
4950 College Blvd.
Overland Park, KS 66211
Phone: (800) 472-5509
Email: info@ntst.com
Web: www.ntst.com
Netsmart helps addiction services providers deliver recovery-based care with Netsmart CareFabric™ (www. whatiscarefabric.com), a tightly woven framework that supports the integrated, coordinated delivery of health services. Our Care Records deliver features to enhance the clinical, financial and operational needs of both inpatient/outpatient addiction treatment.

Nutritional Supplements Corp Inc.
Booth # 204
P.O. Box 36945
Birmingham, AL 35236
Phone: (800) 504-1161
Email: Vitadone@bellsouth.net
Web: www.vitadone.com
Nutritional Supplements Corp provides Vitadone, a nutritional supplement especially developed for methadone patients to help with the side effects that often come with methadone dosing such as constipation, sugar cravings, sweating, and fatigue. We offer Vitadone to clinics on a wholesale basis for resale to patients, or directly to patients.

O.Berk Company of New England/Kols Containers, Inc.
Booth # 220
300 Callegari Drive
West Haven, CT 06516
Phone: (203) 932-8000
Fax: (203) 934-7172
Email: bkersave@oberk.com
Web: www.oberk.com
O.Berk and Kols are full service packaging distributors. We supply “take-home” bottles, child-resistant caps, tamper-evident seals, dispensing cups and gloves. We have warehouses in West Haven, CT and Baltimore, MD with large inventories of bottles and caps to serve your packaging needs.

OraSure Technologies
Booth # 107
220 East 1st Street
Bethlehem, PA 18015
Phone: (610) 882-1820
Email: klauer@orasure.com
Web: www.orasure.com
OraSure Technologies manufactures oral fluid devices and other technologies designed to detect or diagnose critical medical conditions. Its innovative products include rapid tests for HIV and HCV antibodies, influenza antigens, testing solutions for detecting drugs of abuse, and oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications.

Nutritional Supplements Corp Inc.
Booth # 204
P.O. Box 36945
Birmingham, AL 35236
Phone: (800) 504-1161
Email: Vitadone@bellsouth.net
Web: www.vitadone.com
Nutritional Supplements Corp provides Vitadone, a nutritional supplement especially developed for methadone patients to help with the side effects that often come with methadone dosing such as constipation, sugar cravings, sweating, and fatigue. We offer Vitadone to clinics on a wholesale basis for resale to patients, or directly to patients.

O.Berk Company of New England/Kols Containers, Inc.
Booth # 220
300 Callegari Drive
West Haven, CT 06516
Phone: (203) 932-8000
Fax: (203) 934-7172
Email: bkersave@oberk.com
Web: www.oberk.com
O.Berk and Kols are full service packaging distributors. We supply “take-home” bottles, child-resistant caps, tamper-evident seals, dispensing cups and gloves. We have warehouses in West Haven, CT and Baltimore, MD with large inventories of bottles and caps to serve your packaging needs.

OraSure Technologies
Booth # 107
220 East 1st Street
Bethlehem, PA 18015
Phone: (610) 882-1820
Email: klauer@orasure.com
Web: www.orasure.com
OraSure Technologies manufactures oral fluid devices and other technologies designed to detect or diagnose critical medical conditions. Its innovative products include rapid tests for HIV and HCV antibodies, influenza antigens, testing solutions for detecting drugs of abuse, and oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications.
PharmBlue
Booth # 323
PO Box 1858
Cranberry Twp., PA 16066
Phone: (724) 779-4720
Fax: (724) 779-4721
Email: mdelbarone@pharmblue.com
Web: www.pharmblue.com
PharmBlue is an innovative specialty pharmacy offering a unique pharmacy delivery service for patients designed to reduce diversion and improve clinical outcomes in Pain Management, Recovery/Addiction, and Suboxone Clinics. PharmBlue focuses on proprietary protocols and works within federal guidelines to simplify provider-to-patient compliance, ensuring proper treatment and better outcomes.

Reckitt Benckiser Pharmaceuticals
Medical Affairs
Booth # 125
10710 Midlothian Turnpike, Suite 430
Richmond, VA 2325
Phone: (804) 379-1090
Web: www.Indivior.com
Reckitt Benckiser Pharmaceuticals is at the forefront of providing educational resources and treatment options to physicians and patients dealing with opioid dependence. Please visit the company’s medical booth where Reckitt Benckiser Pharmaceutical’s medical personnel will be standing by.

Redwood Toxicology Laboratory, Inc.
An Alere Company
Booth # 102
3650 Westwind Blvd.
Santa Rosa, CA 95403
Phone: (800) 255.2159
Email: sales@redwoodtoxicology.com
Web: www.redwoodtoxicology.com
Redwood Toxicology Laboratory is the government services division of Alere™ and one of the nation’s largest drug and alcohol testing laboratories. We are committed to providing reliable, innovative, and value-focused substance abuse screening products and laboratory services to the government, criminal justice, and treatment marketplaces. We provide confidence in testing.

Roxane Laboratories, Inc.
Booth # 221
1900 Arlington Lane
Columbus, OH 43228
Phone: (888) 831-2183
Fax: (614) 308-3576
Email: coladdictiontherapy.col@boehringer- ingelheim.com
Web: www.roxanne.com
Roxane Laboratories is a recognized leader for the research, development, sales, and marketing of prescription pharmaceuticals. To help support the Addiction Therapy community of clinics and patients, we feature several products in our portfolio, as well as a team of dedicated service professionals. To learn more about Roxane and its products, please visit our website at www.roxane.com.

SAMMS – a Netrix Solution
Booth # 205
2801 Lakeside Drive
Bannockburn, IL 60015
Phone: (877) 717-SAMM
Fax: (800) 789-0954
Email: info@sammssystem.com
Web: www.sammssystem.com
SAMMS, a management solution designed for Behavioral Health Providers, includes Clinical, Financial, Insurance, Compliance and Medication modules. SAMMS can be hosted in the Netrix Cloud or installed on premise. Netrix also offers a wide range of consulting services such as: Clinic Setup and Operations, IT Management and Revenue Cycle Management.

San Diego Reference Laboratory
Booth # 216
6565 Nancy Ridge Drive
San Diego, CA 92121
Phone: (800) 677-7995
Fax: (858) 677-7998
Email: kimberly@sdrl.com
Web: www.SDRL.com
San Diego Reference Laboratory is a client-focused toxicology laboratory, specializing in drug of abuse testing. We offer specifically designed urine/saliva laboratory panels, serum methadone testing, routine clinical tests (CBC, RPR, CMP, Hepatitis, Urinalysis, etc.) and cost effective onsite products to accommodate your program’s needs. SDRL offers clients Quality Service, Accurate Test Results, Accessibility to Technical information, and Rapid Turn Around Time.

Silver Hill Hospital
Booth # 119
208 Valley Road
New Canaan, CT 06840
Phone: (800) 899-4455
Fax: (203) 801-5455
Email: info@silverhillhospital.org
Web: www.silverhillhospital.org
Silver Hill Hospital is a nationally recognized nonprofit psychiatric hospital located in New Canaan, Connecticut - just 50 miles north of New York City. Silver Hill provides acute care and longer-term transitional living programs for adolescents and adults. Specialty programs include Addiction and Co-Occurring Disorders, Chronic Pain and Recovery and Personality Disorders.
Exhibitor Directory

SMART Management, Inc.
Booth # 116
66 Pavilion Avenue
Providence, RI 02905
Phone: (401) 780-2300
Fax: (401) 780-2350
Email: sales@smartmgmt.com
Web: www.smartmgmt.com

SMART’s Electronic Medical Record Software is designed to meet your facility’s every need. SMART Software streamlines your operations from admission to annual report. SMART’s Clinical, Medical and Financial Software Modules integrate any multi-modality treatment facility including Residential or Outpatient Substance Abuse, Methadone Maintenance and Behavioral Health.

Stop Stigma Now
Booth # 322
487 East Main Street, Suite 286
Mount Kisco, NY 10549
Phone: (914) 861-2390
Email: info@stopstigmanow.org
Web: www.stopstigmanow.org

Stop Stigma Now seeks to end the institutional stigmatization related to medication assisted treatment for opioid addiction by providing education, resources and information for representatives of government, political, health and human service agencies; and for the community-at-large.

The Joint Commission
Booth # 110
1 Renaissance Boulevard
Oakbrook Terrace, IL 60181
Phone: (630) 792-5000
Fax: (630) 792-5005
Email: mlehman@jointcommission.org
Web: www.jointcommission.org

Accreditation is a process of externally validating program quality and safety. Joint Commission accreditation is a nationally recognized and respected mark of distinction that demonstrates to those you serve, their families and your community that your program is committed to the highest level of treatment and services. Learn more at jointcommission.org/BHCS.

Tower Systems, Inc.
Booth # 315
17461 Irvine Blvd., Suite Y
Tustin, CA 92780
Phone: (714) 731-0491
Email: info@ towersys.com
Web: www.methadoneclinics.com

Tower Systems has been committed to producing sound and stable software for methadone clinics for over 20 years. We offer a real paperless solution in your sea of paperwork. With a host of CARF, Joint Commission and COA accreditation tools, as well as HIPAA compliant 837 and 835 billing, if its functionality and industry knowledge you’re looking for, look no further than Tower Systems. www.methadoneclinics.com

Treatment Hub 365
Booth # 224
PO Box 61325
Raleigh, NC 27661
Phone: (844) THUB-365
Email: info@treatmenthub365.com
Web: www.treatmenthub365.com

Treatment Hub 365 is the first comprehensive online appointment site for addiction and mental illnesses. Treatment Hub 365 enables individuals to identify their addiction and mental health treatement needs, search available treatment options and make an appointment online instantly. Reducing the stigma and barriers to finding treatment is our mission.

VistaPharm, Inc.
Booth # 117
2224 Cahaba Valley Drive, Suite B3
Birmingham, AL 35242
Phone: (205) 981-1387
Fax: (205) 980-4849
Email: info@vistapharm.com
Web: www.vistapharm.com

VistaPharm, Inc. is a manufacturer and distributor of quality pharmaceutical products. This product line includes Methadone HCl Concentrate in Cherry and Sugar-Free/Dye Free, Methadone Tablets, Methadone Powder, Generic Suboxone (Buprenorphine/Naloxone) Tablets, and Generic Subutex (Buprenorphine) Tablets. Our personalized services set us apart in the Opioid Treatment industry. Please stop by booth 117 to meet our staff.

Wedgewood Pharmacy
Booth # 302
405 Heron Drive, Suite 200
Swedesboro, NJ 08085
Phone: (800) 331-8272
Fax: (800) 589-4250
Email: info@wedgewoodpharmacy.com
Web: www.WedgewoodRx.com

Compliance is key to a successful outcome. So when you choose to prescribe custom-compounded Naltrexone, Naloxone or Disulfiram, you can depend on PCAB accredited Wedgewood Pharmacy for innovative dosage forms that may help ensure compliance. Trust us for consistency, quality, convenience and world-class customer care.

Weston Medical Publishing/Journal of Opioid Management
Booth # 200
470 Boston Post Road, Suite #301
Weston, MA 02493
Phone: (781) 899-2702
Fax: (781) 899-4900
Email: jom@pnpco.com
Web: www.opioidmanagement.com

Weston Medical Publishing, LLC is a leading publisher of professional peer-reviewed scientific, technical, and medical (STM) journals. Journal of Opioid Management, its premier publication, is the only peer-reviewed reference and clinical journal that deals with all aspects of opioids from basic science to clinical application to abuse and addiction medicine.

White Deer Run/Cove Forge BHS/Bowling Green Brandywine
Booth # 109
WDR Marketing Office
220 North Front Street, Suite 4
Philipsburg, PA 16866
Phone: (814) 861-6198
Fax: (814) 861-6199
Email: slopashanski@crchealth.com
Web: www.whitedeerrun.com

White Deer Run/Cove Forge BHS/Bowling Green Brandywine is one of the leading systems in the treatment of drug and alcohol addiction in Pennsylvania and offers a comprehensive network of specialized behavioral health care services. Our facilities provide a relaxed atmosphere that lends itself to personal reflection and healing for adults and adolescents.
The American Association for the Treatment of Opioid Dependence, Inc. (AATOD) currently has members representing 29 states including the District of Columbia and Mexico, which include approximately 900 treatment programs throughout the United States. We also have individual member programs in 11 other states.

Since AATOD works on behalf of all our members (and indeed, the treatment field as a whole), all members and patients share in our successes. However, AATOD’s strength depends entirely on the strength of our membership, and we would like to include as many states, programs and individuals as possible in the effort.

These are the 3 categories a member can fall within:
- Program Membership
- Individual Membership
- State Membership

For more information on becoming a member, visit the AATOD Booth (#108) or www.aatod.org.
Conference Sponsors

The American Association for the Treatment of Opioid Dependence, Inc. and the 2015 Conference Planning Committee acknowledge and give special thanks to:

Georgia Department of Behavioral Health and Developmental Disabilities (DBHDD)

Opioid Treatment Providers of Georgia (OTPG)

National Institute of Health (NIH)/National Institute of Drug Abuse (NIDA)

Substance Abuse and Mental Health Services Administration (SAMHSA)

PLATINUM LEVEL SPONSORS
- Atlantic Diagnostic Laboratories
- Mallinckrodt Pharmaceuticals
- VistaPharm

SILVER LEVEL SPONSORS
- Addiction Treatment Providers Insurance Program
- Alkermes, Inc.
- Boehringer Ingelheim – Roxane Laboratories, Inc.
- C&C Containers, LLC
- CARF International
- Colonial Management Group
- CRC Health Group
- Indivior (Reckitt Benckiser Pharmaceuticals Inc. is a subsidiary of Indivior PLC)
- Gallagher Bollinger
- Laboratory Corporation of America (LabCorp)
- Netsmart Technologies, Inc.
- Orexo US, Inc.
- The Joint Commission

BRONZE LEVEL SPONSORS
- Alliance Recovery
- O.Berk New England, LLC & Kols Container, Inc.
- Private Clinic
- Southeast Addiction Technology Transfer Center

ADDITIONAL SPONSORS
- ACM Medical Laboratories
- American Society of Addiction Medicine (ASAM)
- Brown
- Naples Medical Devices, LLC
- PharmBlue
- Tower Systems, Inc.

October 29-November 2, 2016
Baltimore Marriott Waterfront
Baltimore, Maryland
www.aatod.org